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(57) ABSTRACT 
Methods are described that bias cells, such as potent and 
multipotent stem cells, by transfection with a nucleic acid 
sequence, to differentiate to a desired end-stage cell or a cell 
having characteristics of a desired end-stage cell. In particular 
embodiments, human neural stem cells are transfected with 
vectors comprising genes in the homeobox family of tran-
scription factor developmental control genes, and this results 
in a greater percentage of resultant transformed cells, or their 
progeny, differentiating into a desired end-stage cell or a cell 
having characteristics of a desired end-stage cell. 
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METHODS AND PRODUCTS FOR BIASING 
CELLULAR DEVELOPMENT 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
reflect different characteristics of localized multipotent stem 
cells (Stem Cell Biology, Marshak et al., pp 418-419). 
One advantage of use of mulitpotent and more committed 
cells further along in differentiation, compared to pluripotent 
embryonic stem cells, is the reduced possibility that some 
cells introduced into an organism from such source will form 
a tumor (Stem Cell Biology, Marshak et al., p. 407). However, 
a disadvantage of cells such as cell types developed from 
multipotent stem cells, for instance, embryonic progenitor 
This application claims priority to U.S. Ser. No. 60/621, 
483 filed Oct. 22, 2004; and is a divisional application of U.S. 
application Ser. No. 11/258,603, filed Oct. 24, 2005 now U.S. 
Pat. No. 8,080,420, which are hereby incorporated in their 
entirety. 
FIELD OF INVENTION 
10 cells, is that they are not amenable to ongoing cell culture. For 
instance, embryonic neural progenitor cells, which are able to 
differentiate into neurons and astrocytes, are reported to sur-
vive only one to two months in a cell culture. 
Generally, it is known in the art that the lack of certain 
15 factors critical to differentiation will result in no or improper 
differentiation of a stem cell. Researchers also have demon-The present invention is directed to methods and systems 
directed to altering the differentiation of a cell, more particu-
larly to biasing a multipotent stem cell by transfecting the cell 
with a nucleic acid sequence comprising a desired gene, the 
gene being expressed so that the cell, or its progeny, differ- 20 
entiate to a desired end-stage cell. 
BACKGROUND 
strated that certain factors may be added to a culture system 
comprising stem cells, such as embryonic stem cells, so that 
differentiation to a desired, stable end-stage differentiated 
cell proceeds. It also is known in the art to introduce and 
express a transcription factor gene, Nurrl, into embryonic 
stem cells, and then process the cells through a five-step 
differentiation method (Kim, Jong-Hoon et al., Dopamine 
Neurons Derived from Embryonic Stem Cells Function in an 
Proper cellular function and differentiation depends on 
intrinsic signals and extracellular environmental cues. These 
signals and cues vary over time and location in a developing 
organism (i.e., during embryogenesis ), and remain important 
25 Animal Model of Parkinson's Disease, Nature, 418:50-56 
(2002)), resulting in differentiated cells having features of 
dopaminergic cells. However, the starting cell for this was an 
embryonic stem cell, and the differentiation process through 
to a cell having the features of a dopaminergic neuron, in developing and differentiating cells during post-natal 
growth and in a mature adult organism. Thus, in a general 
sense, the interplay of the dynamically changing set of intra-
cellular dynamics (such as manifested by intrinsic chemical 
signaling and control of gene expression) and environmental 
influences (such as signals from adjacent cells) determine 
cellular activity. The cellular activity so determined is known 35 
to include cell migration, cell differentiation, and the manner 
30 requires substantial effort that includes the addition and con-
trol of endogenous factors. In addition, because the starting 
cell is an early-stage embryonic stem cell having pluripo-
tency, there is a relatively higher risk that some cells 
a cell interacts with surrounding cells. 
implanted from this source will become tumerogenic. 
Also, without being bound to a particular theory, it is 
believed that to the extent a particular method of differentia-
tion results in a greater percentage of cells that are dedicated 
or predetermined to differentiate to a desired functional cell 
type (i.e., a cholinergic neuron), this reduces the chance of 
40 tumor formation after introduction of cells derived from such 
The use of stem cells and stem-cell-like cells of various 
types for cell replacement therapies, and for other cell-intro-
duction-based therapies, is being actively pursued by a num-
ber of researchers. Embryonic stems cells from a blastocyst 
stage are frequently touted for their pluripotency-that is, 
their ability to differentiate into all cell types of the develop-
ing organism. Later-stage embryonic stem cells, and certain 
cells from generative areas of an adult organism, are identi- 45 
fied as more specialized, multipotent stem cells. These cells 
include cells that are able to give rise to a succession of a more 
limited subset of mature end-stage differentiated cells of par-
ticular types or categories, such as hematopoietic, mesenchy-
mal, or neuroectodermal end-stage differentiated cells. For 50 
example, a multipotent neural stem cell may give rise to one 
or more neuron cell types (i.e., cholinergic neuron, dopamin-
ergic neuron, GABAergic neurons), which includes their spe-
cific cell classes (i.e., a basket cell or a chandelier cell for 
GABAergic neurons), and to non-neuron glial cells, such as 55 
astrocytes and dendrocytes. 
Further along the path of differentiation are cells derived 
from multipotent stem cells. For example, derivatives of a 
localized, non-migrating neuroectodermal type stem cell may 
migrate but, compared to their multipotent parent, have more 60 
limited abilities to self-renew and to differentiate (See Stem 
Cell Biology, Marshak, Gardner & Gottlieb, Cold Spring 
Harbor Laboratory Press, 2001, particularly Chapter 18, p. 
407). Some of these cells are referred to a neuron-restricted 
precursors ("NRPs"), based on their ability, under appropri- 65 
ate conditions, to differentiate into neurons. There is evidence 
that these NRPs have different subclasses, although this may 
method. As disclosed herein, embodiments of the present 
method that utilize multipotent stem cells as the starting 
material provide an increased percentage of cells predisposed 
(i.e., biased) to or differentiated to a desired cell type. This is 
believed to provide for reduced risk of tumor formation 
equivalent to or superior to the use of more differentiated cells 
such as NRPs. 
There are many possible applications for methods, compo-
sitions, and systems that provide for improved differentiation 
of stem cells to a desired functional, differentiated cell. For 
example, not to be limiting, millions of people suffer from 
deafness and balance defects caused by damage to inner ear 
hair cells (IEHCs ), the primary sensory receptor cells for the 
auditory and vestibular system after exposure to loud noises, 
antibiotics, or antitumor drugs. Since IEHCs rarely regener-
ate in mammals, any damage to these organs is almost irre-
versible, precludes any recovery from hearing loss, and 
results in potentially devastating consequences. Current 
therapies utilizing artificial cochlear implants or hearing aids 
may partially improve but not sufficiently restore hearing. 
Therefore, cell therapy to replace the damaged IEHC may be 
one of the most promising venues today. In the past, IEHC 
production from progenitor cells from the vestibular sensory 
epithelium of the bullfrog {Cristobal, 1998 #28} and possible 
existence of IEHC progenitors in mammalian cochlea sen-
sory epithelia {Kojima, 2004 #29} has been reported. How-
ever limited quantity of IEHC progenitor prevents clinical 
US 8,513,017 B2 
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application of this type of cell to treat deafness. Thus novel 
technology to produce IEHCs from other cell sources is 
needed. 
While stem cells are known to be the building blocks 
responsible for producing all of a body's cells, the specific 5 
differentiation process towards to IEHC linage is not clear. 
Embryonic stem cells transplanted into the inner ear of adult 
mice or embryonic chickens did not differentiate into IEHCs 
{Sakamoto, 2004 #19}. Neural stem cells (NSCs) grafted into 
the modiolus of cisplatin-treated cochleae of mice only dif- 10 
ferentiated into glial or neuronal cells within the cochleae 
{Tamura, 2004 #18}. In order to produce IEHCs from these 
stem cells, modification or direction of the cell fate decision 
4 
FIG. 12: Differentiated HNSCs/Lhx8 in co-culture with 
LA-N-2 cells. Cells were double-immunofluorescence 
stained with (a) ~III-tubulin (red) and (b) ChAT (green), 
markers for colinergic neurons (c) two localization of ~III­
tubulin and ChAT. Blue signal is a counter staining for nuclei 
by DAPI. 
FIG. 13: Differentiated HNSCs/LHX8 in co-culture with 
law and 2 cells. Cells were double immunofluorescence 
stained with (a) ~III-tubulin (green) and (b) CHAT (red), 
markers for colinergic neurons (c) co-localization of ~III­
tubulin and CHAT. (20x magnification) blue signal is a 
counter staining for nuclei for DAPI. ( d) insert for nonO-
specific staining for c ~III-tubulin and CHAT, respectively. 
FIG. 14 Differentiated HNSCs/Lhx8 in co-culture with 
may be needed. 
Another possible application for methods, compositions, 
and systems of the present invention is biasing Human Neural 
Stem Cells ("HNSCs") to differentiate to cholinergic neu-
rons, or to cells having characteristics of cholinergic neurons. 
15 LA-N-2 cells. A) ~III-tubulin (green) and b) ChAT (red), 
markers for cholinergic neurons, c) co-localization of ~III­
tubulin & ChAT. Blue signal is a counter staining for nuclei by 
DAPI ( 40x magnification). 
FIG. 15 Differentiated non-transfected HNSCs in co-cul-
Such biasing would provide for an improved percentage of 20 ture with LA-N-2 cells. Cells were double-immunofluores-
such stem cells in a culture vessel to differentiate to this 
desired end-stage nerve cell. Improvements to the percentage 
of cells that are known to be biased to differentiate to this 
end-stage neuron cell, or to cells having characteristics of a 
cholinergic neuron, may lead to improvements both in 25 
research and treatment technologies for diseases and condi-
tions that involve degeneration or loss of function of cholin-
ergic neurons. Alzheimer's disease is one example of a 
malady known to be associated with degeneration of the 
long-projecting axons of cholinergic neurons. 30 
Thus, there is a need in the art to improve the compositions, 
methods and systems that provide biased and/or differenti-
ated cells from stem cells or stem-cell-like cells. More par-
ticularly, a need exists to obtain a higher percentage of desired 
cells from a pre-implantation cell culture, such as starting 35 
from multipotent stem cells and obtaining a higher percent-
age of cells committed to differentiate to a specified type of 
functional nerve cell, such as cholinergic neurons or inner ear 
hair cells. The present invention addresses these needs. 
40 
BRIEF DESCRIPTION OF THE FIGURES 
cence stained with ~III-tubulin (green) and nuclei counter 
staining by DAPI (Blue). No Chat-positive neurons were 
observed. (a-b) !Ox and (c) 20x magnification, respectively. 
FIG. 16 Differentiated non-transfected HNSCs in co-cul-
ture with LA-N-2 cells. Cells were double-immunofluore-
scense stained with (a-b) ~III-tubulin (green) and (c) GFAP 
(red) markers for neurons and astrocytes, respectively. Blue 
signal is a counter staining for nuclei by DAPI. 
DETAILED DESCRIPTION OF EMBODIMENTS 
OF THE INVENTION 
In reviewing the detailed disclosure which follows, and the 
specification more generally, it should be borne in mind that 
all patents, patent applications, patent publications, technical 
publications, scientific publications, and other references ref-
erenced herein are hereby incorporated by reference in this 
application in order to more fully describe the state of the art 
to which the present invention pertains. 
Reference to particular buffers, media, reagents, cells, cul-
ture conditions and the like, or to some subclass of same, is 
not intended to be limiting, but should be read to include all 
such related materials that one of ordinary skill in the art 
would recognize as being of interest or value in the particular 
FIGS. 1-16 are appended hereto, are part of the specifica-
tion, and are described herein and/or on the figures them-
selves. 
FIG. 3Math1 full lengthmRNA was amplified by RT-PCR 
and digested with Apai, which cuts position 441 of 
HathlORF. Expecting fragment sizes are 441 bp and 624 bp. 
45 context in which that discussion is presented. For example, it 
is often possible to substitute one buffer system or culture 
medium for another, such that a different but known way is 
used to achieve the same goals as those to which the use of a 
M: 100 bp marker; 5, 6, without transfection (control); 7, 8: 
transfected with mammarian expression vector containing 50 
Hath2. 
suggested method, material or composition is directed. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
unless defined herein, are intended to have the same meaning 
as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 
FIG. 9: Phase contrast micrographs of LA-N2 cells. FIG. 
9a: LA-N2 cells grow in clusters as adherent fibroblasts-like 
cells, occasionally cells extend short processes and form neu-
ronal-like networks. FIG. 9b: LA-N2 cells treated with 10-6 
µM retinoic acid. 
FIG. 10: Lhx8 expression in the LA-N-2 and HNSCs cells. 
55 to one of ordinary skill in the art, unless stated otherwise. For 
purposes of more clearly facilitating an understanding the 
invention as disclosed and claimed herein, the following defi-
nitions are provided. FIG. lOa: Shows gene expression with RT-PCR analysis of 
LA-N-2 cells treated with ten µM RA showed an increased 
expression ofLhx8 (394 bp) and ChAT (splice variants -600 60 
and 400 bp, respectively, compared with non-treated cells. 
FIG. lOb: represents RT-PCR analysis ofLhx8 expression in 
HNSCs 48 hours post-transfection. 
FIG. 11: In vitro differentiation of Lhx8-transfected 
HNSCs. HNXCs transfected with Lhx8 (a) in co-culture with 65 
LA-N-2 cells and serum-free conditions differentiated mostly 
neurons with long extended processes after 10-14 days (b-f). 
DEFINITIONS 
Stem cells are undifferentiated cells that exist in many 
tissues of embryos and adult organisms. In embryos, blasto-
cyst stem cells are the source of cells that differentiate to form 
the specialized tissues and organs of the developing fetus. In 
adults, specialized stem cells in individual tissues are the 
source of new cells, replacing cells lost through cell death due 
US 8,513,017 B2 
5 
to natural attrition, disease, or injury. Stem cells may be used 
as substrates for producing healthy tissue where a disease, 
disorder, or abnormal physical state has destroyed or dam-
aged normal tissue. 
Five defining characteristics of stem cells have been 
advanced (from Weiss et al., 1996). That is, stems cells gen-
erally are recognized as having the ability to: 
1. Proliferate: Stem cells are capable of dividing to produce 
daughter cells. 
2. Exhibit self-maintenance or renewal over the lifetime of 10 
the organism: Stem cells are capable of reproducing by 
dividing symmetrically or asymmetrically to produce 
new stem cells. Symmetric division occurs when one 
stem cell divides into two daughter stem cells. Asym-
metric division occurs when one stem cell forms one 15 
new stem cell and one progenitor cell. Symmetric divi-
sion is a source of renewal of stem cells. This permits 
stem cells to maintain a consistent level of stem cells in 
an embryo or adult mammal. 
3. Generate large number of progeny: Stem cells may pro- 20 
duce a large number of progeny through the transient 
amplification of a population of progenitor cells. 
4. Retain their multilineage potential over time: The vari-
ous lines of stem cells collectively are the ultimate 
source of differentiated tissue cells, so they retain their 25 
ability to produce multiple types of progenitor cells, 
which in turn develop into specialized tissue cells. 
5. Generate new cells in response to injury or disease: This 
is essential in tissues which have a high turnover rate or 
which are more likely to be subject to injury or disease, 30 
such as the epithelium or blood cells. 
Thus, key features of stem cells include their capability of 
self-renewal, and their capability to differentiate into a range 
of end-stage differentiated tissue cells. 
By "neural stem cell" (NSC) is meant a cell that (i) has the 35 
potential of differentiating into at least two cell types selected 
from a neuron, an astrocyte, and an oligodendrocyte, and (ii) 
exhibits self-renewal, meaning that at a cell division, at least 
one of the two daughter cells will also be a stem cell. Gener-
ally, the non-stem cell progeny of a single NSC are capable of 40 
differentiating into neurons, astrocytes, Schwarm cells, and 
oligodendrocytes. Hence, a stem cell such as a neural stem 
cell is considered "multipotent" because its progeny have 
multiple differentiative pathways. Under certain conditions 
an NSC also may have the potential to differentiate as another 45 
non-neuronal cell type (e.g., a skin cell, a hematopoietic cell, 
a smooth muscle cell, a cardiac muscle cell, a skeletal muscle 
cell, a bone cell, a cartilage cell, a pancreatic cell or an 
adipocyte ). 
By "Human Neural Stem Cell" ("HNSC") is meant a neu- 50 
ral stem cell of human origin. A HNSC may be of fetal origin, 
6 
By "potent cell" is meant a stem cell that has the capability 
to differentiate into a number of different types of end-stage 
cell types, and to self-renew, and may include stem cells 
classified as pluripotent, multipotent, or cells more differen-
tiated than multipotent (i.e., a dedicated progenitor) under 
different stem cell classification schemes. 
By "a presumptive end-stage cell" is meant a cell that has 
acquired characteristics of a desired end-stage cell type, but 
which has not been conclusively identified as being the 
desired end-stage cell. A presumptive end-stage cell pos-
sesses at least two, and often more, morphological and/or 
molecularphenotypic properties of the desired end-stage cell. 
The practice of the present invention will employ, unless 
otherwise indicated, conventional techniques of cell biology, 
cell culture, molecular biology, transgenic biology, microbi-
ology, recombinant DNA, and immunology, which are within 
the skill of the art. Such techniques are explained fully in the 
literature. See, for example, Molecular Cloning A Laboratory 
Manual, 3rd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold 
Spring Harbor Laboratory Press: 2001); DNA Cloning, Vol-
umes I and II (D. N. Glover ed., 1985); Oligonucleotide 
Synthesis (M. J. Gait ed., 1984); Mullis et al., U.S. Pat. No. 
4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. 
Higgins eds. 1984); Transcription And Translation (B. D. 
Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells 
(R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells 
And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide 
To Molecular Cloning (1984 ); the treatise, Methods In Enzy-
mology (Academic Press, Inc., N.Y.); Gene Transfer Vectors 
For Mammalian Cells (J. H. MillerandM. P. Calos eds., 1987, 
Cold Spring Harbor Laboratory); Methods In Enzymology, 
Vols. 154 and 15 5 (Wu et al. eds.), Immunochemical Methods 
In Cell And Molecular Biology (Mayer and Walker, eds., 
Academic Press, London, 1987); Handbook Of Experimental 
Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, 
eds., 1986); Manipulating the Mouse Embryo, (Cold Spring 
Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). 
U.S. Patent Application Nos. 2003/0219898, 2003/ 
0148513, and 2003/0139410 are incorporated by reference to 
the extent they are not inconsistent with the teachings herein. 
The first two of these patent applications describe multiple 
uses of increased potency cells obtained from the taught 
methods, and in particular, the implantation of stem cells for 
different therapeutic treatments of neurological trauma and 
degenerative conditions. The third patent application is 
directed to the use of certain compounds to stimulate prolif-
eration and migration of stem cells. Those skilled in the art 
will readily appreciate that the cells of the present invention 
could be obtained, or their effectiveness enhanced, by com-
bining with the teachings of the aforementioned patent appli-
cations, without undue experimentation. 
The present invention is directed to compositions, methods 
and systems that provide for increased percentage of neural 
stem cells and other multipotent or potent stem cells to 
become committed, or predisposed, to differentiate to a 
desired end-stage differentiated nerve cell. More particularly, 
the present invention utilizes the introduction into such a stem 
cell of a nucleic acid sequence comprising a developmental 
control gene. A developmental control gene as used in the 
or adult origin from a neural source, or may be derived from 
other cell sources, such as by de-differentiating a cell of 
mesenchymal origin. As to the latter, for example see U.S. 
application serial number 2003/0219898, which is incorpo- 55 
rated by reference, inter alia, specifically for this teaching. 
HNSCs of the invention are distinguished from natural 
HNSCs by their adaptation for proliferation, migration and 
differentiation in mammalian host tissue when introduced 
thereto. 60 present invention may encode a transcription factor, cell-
surface molecule, or a secreted signal molecule (See Funda-
mental Neuroscience, Zigmond, Bloom, Landis, Roberts and 
Squire, Academic Press, 1999, Chapter 15). Examples below 
provide details of the introduction of three transcription factor 
By a "population of cells" is meant a collection of at least 
ten cells. A population may consist of at least twenty cells, or 
of at least one hundred cells, or of at least one thousand or 
even one million cells. Because the NSCs of the present 
invention exhibit a capacity for self-renewal, they can be 
expanded in culture to produce a collection oflarge numbers 
of cells. 
65 type genes-Lhx8 and Gbxl that improve differentiation of 
human neural stem cells (HNSCs) to cells having character-
istics of cholinergic neurons, and Hath! that improves differ-
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entiation ofHNSCs to cells having characteristics of inner ear 
hair cells (IEHCs ). The effectiveness of these single-gene 
introductions to such cells is unexpected and surprising in 
view of the subtlety and complexity of differentiation of 
multipotent stem cells to cells such as neural cells like cho-
linergic nerve cells and inner ear hair cells. Other develop-
ment control genes having capability to achieve similar 
desired results are disclosed. 
8 
to affect developmental progression, rather than fate, of 
motor neurons, which suggests a role of cell-to-cell signaling 
in the embryo to fully effectuate the differentiation in vivo 
(Fundamental Neuroscience, Zigmond et al., pp. 443-444). 
These highly specialized and variable roles for homeobox 
genes in general, and for LIM family homeobox genes more 
particularly, demonstrate the subtle, specific, and highly vari-
able effects that these genes may have on cell and tissue 
development and differentiation. 
Further with regard to function ofhomeobox genes, these 
genes encode transcriptional regulators that play critical roles 
in a variety of developmental processes. Although the genetic 
and developmental mechanisms that control the formation of 
forebrain cholinergic neurons are just beginning to be eluci-
The present invention advances the art by demonstrating 
the utility, in multipotent stem cells, of introducing for 10 
expression a nucleic acid sequence that comprises a desired 
developmental control gene. One example of such introduc-
ing is transfection by a vector comprising the nucleic acid 
sequence. After such introducing, the introduced develop-
mental control gene is expressed in the cell (or its progeny), at 
least transiently. By so altering a multipotent stem cell, the 
present invention provides for more consistent differentiation 
15 dated, it is known that the vast majority offorebrain cholin-
ergic neurons derive from a region of the subcortical telen-
cephalon that expresses the Nkx2-1 homeobox gene. 
to a desired functional cell type, such as a cholinergeric nerve 
cell. In doing so, this is believed to reduce known risks ofthis 
type of cell transplantation, such as the risk of tumor growth 
upon implantation of cells from pluripotent embryonic cell 
cultures. 
It has recently been reported that Nkx2-1 appears to 
specify the development of the basal telencephalon by posi-
20 tively regulating transcription factors such as the LIM-ho-
meobox genes Lhx8 (also known as L3 or Lhx7) and Gbxl, 
which are associated with the development of cholinergic 
neurons in the basal forebrain (Zhao et al., 2003; Asbreuk et Thus, in some embodiments the present invention is 
directed to biasing a multipotent cell such that the cell 
becomes progranmied, or biased, to differentiate into a 25 
desired cell type under appropriate external conditions. This 
al., 2002, Waters et al., 2003). 
In the spinal cord, IsLl, Lhxl, Lhx3 and Lhx4 have been 
shown to be important for the development of spinal cord 
cholinergic neurons (Pfaff et al., 1996; Sharma et al., 1998; 
Kania et al., 2000). Given that the spinal cord cholinergic 
neurons are reported to require multiple LIM-homeobox 
is done in some embodiments so that in a pre-implantation 
cell culture a greater percentage of cells are either pre-dis-
posed to differentiate to and/or do differentiate to a desired 
cell type. More particularly, in certain embodiments of this 
biasing, the cell is transformed so it expresses a certain factor 
that biases the same cells to differentiate to a desired cell type 
upon a later implantation to a particular tissue in a living 
organism. In such embodiments, this improves a differentia-
tion ratio so that a higher percentage of cells introduced into 
a particular cell medium, a tissue culture, or a living organism 
in a particular location differentiate into the end-stage differ-
entiated cell type that is desired. Without being bound to a 
particular theory, this is believed to increase the probability of 
success and overall effectiveness, and to decrease the risks 
associated with implantation of cells obtained from embry-
onic stem cells or embryonic-cell-like cells. 
While not meant to be limiting as to the type of nucleic acid 
sequence introduced, examples herein utilize introduction to 
30 genes for their development, it is expected that Lhx8 is not the 
only LIM-homeobox gene that is required in generating 
telencephalic cholinergic neurons. Other candidates are Lhx6 
and IsLl, which are also expressed in the basal telencephalon 
(Marin et al., 2000). Also, it is suggested that Dlxl/2 and 
35 Mash, though not directly regulating Lhx8, participate in 
controlling the number of cholinergic neurons that are formed 
in the telencephalon (Marin et al., 2000). 
Thus, at a minimum, developmental control genes that may 
be used in the present invention to transfect cells to bias those 
40 cells (or their progeny) to differentiate to a desired end-stage 
cell type, here that cell type being cholinergic neurons, 
include, but are not limited to Lhx8, Gbxl, Lhx6, IsLl, 
Dlxl/2 and Mash. 
The Human Neural Stem Cells (HNSCs ), such as discussed 
45 in the examples below, are obtained from cultures that were 
started from clones obtained from human fetal brain tissue. 
One lineage was obtained by isolating individual cells from 
neurospheres of a fetal brain tissue sample obtained from 
Cambrex, and ultimately identifying one multipotent stem 
a cell of a nucleic acid sequence comprising a homeobox 
gene. This is a gene group that includes a number of known 
developmental control genes. A homeobox gene is a gene 
containing an approximately 180-base-pair segment (the 
"homeo box") that encodes a protein domain involved in bind-
ing to (and thus regulating the expression of) DNA. The 
homeobox segment is remarkably similar in many genes with 
different functions. However, specific homeobox genes are 
known to operate at different stages, and in different tissue 
environments, to yield very different specific results. For 
example, in relatively early embryological development in 
the vertebrate embryo, expression of genes of the Hox family 
ofhomeobox genes appears to affect development of the brain 
based on position along the anterior/posterior axis. This is 
believed to control identity and phenotypic specializations of 
individual rhombomeres. (Fundamental Neuroscience, Zig-
mond et al., p. 435). Later in development, LIM homeobox 
gene expression is associated with the projection pattern of 
developing primary motor neurons, and more generally, 
expression of a particular combination of LIM homeobox 
genes appears to be related to motor neuron subtype identity 65 
and to targeting specificity (Fundamental Neuroscience, Zig-
mond et al., p. 507). Also, some LIM homeobox genes appear 
50 cell for clonal propagation. A second lineage was obtained by 
isolating a desired multipotent cell from a 9-week old fetal 
brain (Christopher L. Brannen and Kiminobu Sugaya, Neu-
roreport 11, 1123-8 (2000)). The HNSCs so obtained were 
maintained in seruni-free medium, and have been demon-
55 strated to have the capability to differentiate into neurons and 
glial cells such as astrocytes and dendrocytes. 
The following examples are provided to further disclose 
the genesis, operation, scope and uses of embodiments of the 
present invention. These examples are meant to be instruc-
60 tive, and illustrative, and not to be limiting as to the scope of 
invention as claimed herein. These examples are to be con-
sidered with the referred to drawings. 
EXAMPLE 1 
This example demonstrates that transfection of a human 
neural stem cell with Hath! results in the transfected cell (or 
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its progeny) differentiating into a cell having markers of an 
inner ear hair cell (IEHC). Hathl (in humans) and Mathl (in 
mice) are basic helix-loop-helix transcription factors (and 
homologs of the Drosophila gene atonal) that are expressed in 
inner ear sensory epithelia. Since embryonic Mathl-null 5 
mice failed to generate cochlear and vestibular hair cells, it 
appears to be required for the generation of inner ear hair cells 
(Bermingham N A, Hassan B A, Price S D, Vollrath M A, 
Ben-Arie N, Eatock RA, Bellen HJ, Lysakowski A, Zoghbi 
HY. 1999. Mathl: An essential gene for the generation of 10 
inner ear hair cells. Science 284 (June 11): 1837-1841). Fate 
determination of mammalian IEHC is generally completed 
by birth. However, overexpression of Mathl in postnatal rat 
cochlear explant cultures resulted in production of extra hair 
cells from columnar epithelial cells located outside the sen- 15 
sory epithelium, which normally give rise to inner sulcus 
cells. Mathl expression also facilitated conversion of postna-
tal utricular supporting cells into hair cells (Zheng, G L, Gao 
Wq. 2000. Overexpression ofHathl induces robust produc-
tion of extra hair cells in postnatal rat inner ears. Nat Neuro- 20 
science June; 3(6):580-6). In vivo, Mathl overexpression 
leads to the appearance of immature hair cells in the organ of 
Corti and new hair cells adjacent to the organ of Corti in the 
interdental cell, inner sulcus, and Hensen cell regions, indi-
cating nonsensory cells in the mature cochlea retain the com- 25 
petence to generate new hair cells after over expression of 
Mathl (Kawamoto K, Ishimoto S, Minoda R, Brough D E, 
Raphael Y. 2003. Mathl gene transfer generates new cochlear 
hair cells in mature guinea pigs in vivo. J Neurosci June 1; 
23(11 ):4395-400). Based on the above-summarized work, it 30 
was hypothesized that Hathl may be necessary, and sufficient 
as a single introduced gene for expression in a multipotent 
neural stem cell, to positively affect differentiation to an 
IEHC, or to a cell having characteristics of an IEHC. 
A Hathl gene (SEQ ID N0:4) was amplified from the 35 
homo sapiens BAC clone RPl 1-680117 by PCR and then 
cloned it into a manimalian expression directional cloning 
vector, pcDNAHismax TOPO TA (See FIG. 1; 6x His tag 
disclosed as SEQ ID NO: 16). Upon the insertion of the Hathl 
gene expressible sequence into the directional cloning vector, 40 
the expressible sequence was operatively linked to the CMV 
promoter, and was also positioned upstream (with regard to 
reading) of a polyadenylation transcription termination site. 
The clone was confirmed by sequencing of the insert. 
An established a non-serum HNSC culture system was 45 
utilized to investigate the differentiation of human neural 
stem cells (HNSCs) within a defined condition. (Christopher 
L. Brannen and Kiminobu Sugaya, Regeneration and Trans-
plantation, 11:5, 1123-1128 (2000)). The serum-free supple-
mented growth medium consisted of HAMS-F12 (Gibco, 50 
BRL, Burlington, ON), antibiotic/antimycotic mixture 
(1:100, Gibco), B27 (1:50, Gibco), human recombinant 
FGF-2 and EGF (20 ng/ml each, Rand D Systems, Minne-
apolis, Minn.), and heparin (5 ug/ml, Sigma, St. Louis, Mo.). 
Cells were maintained in 20 ml of this medium at 37° C. in a 55 
5% co2 humidified incubation chamber. 
10 
cells resembled morphology of IEHC. The calretinin expres-
sion in the culture was also confirmed by Western blot, which 
showed single band specific to calretinin molecular weight 
(29 kD). Further electron microscopy analysis of the cells 
also showed a typical IEHC morphology. These results indi-
cate that HNSCs transfected with a vector comprising a Hathl 
gene differentiate into IEHCs or into cells having character-
istics of IEHCs. Comparisons with non-transfected controls 
using Western blot and room temperature PCR showed the 
presence of Hathl protein and Hathl mRNA in cells trans-
fected with Hathl, but not in the controls. 
Thus, embodiments of the present method provide for 
improved approaches to obtain IEHCs, or cell having char-
acteristics ofIEHCs, that are derived from HNSCs. Embodi-
ments of the present invention provide a higher percentage of 
a population of cells biased, or disposed, to differentiate to 
IEHCs, or to cells having characteristics of IEHCs. The 
HNSCs utilized in this example are readily and continuously 
cultured in serum-free culture medium. Without being lim-
ited, in vitro and in vivo studies and trials using cells so 
obtained from HNSCs may include electrophysiological 
assessment of the cells and investigation of functional recov-
ery after transplantation of the cells into the animal model of 
deafness. Positive findings in such pre-clinical studies may 
advance the art farther toward treatment of deafness via cell 
transplantation therapy using IEHCs produced from HNSCs. 
Material and Methods 
Hath 1 Transfection 
The human Hathl gene (SEQ ID NO: 1) is amplified from 
the Homo sapiens BAC clone RPl 1-680117 by PCR, using a 
forward primer (5'-TCCGATCCTGAGCGTCCGAGCCTT-
3', SEQ ID NO: 14) and reverse primer (5'-GCTTCTGTCAC-
CTTCCTAACTTGCC-3', SEQ ID N0:15). The PCR ampli-
fication is conducted in 20 µl volumes containing the BAC 
clone (100 ng), 1 x amplification buffer, 1 µM of each primer, 
dNTP Mix (250 µM), and Taq DNA Polymerase (2.5 U). The 
PCR condition is 95° C. (30"), 59° C. (30"), 72° C. (60") for 
35 cycles, with an initial denaturation of95° C. (5') and final 
elongation of 72° C. (15'). The PCR amplified fragment is 
cloned into a directional pcDNAHismax TOPO TA vector 
and the clone is confirmed by sequencing of the insert. 
The gene expression ofHathl is assessed by RT-PCR with 
the following condition: 95° C. (60"), 56° C. (60"), 72° C. 
(60") for 35 cycles, with an initial denaturation of95° C. (5') 
and final elongation of72° C. (15'). The Hathl gene is trans-
fected into Human Neural Stem Cells (HNSCs) using the 
Neuroporter Kit. The Neuroporter kit utilizes a lipid-based 
transfection system for the use with cultured primary neu-
rons, neuronal cell lines, and glial cells. DNA and Neu-
roporter are used in a ratio of 10 µg DNA/75 µl Neuroporter, 
utilizing 37.5 µl per well in a 6-well plate and with total 
volumes of 1.5 mL growth media per well. 10 µg of DNA is 
added to DNA Diluent to make a total volume of 125 µl; this 
is incubated for 5' at room temperature. 75 µl of the Neu-
roporter Reagent is added to serum-free media to make a final 
volume of 125 µ!.These solutions are incubated for 10 min-
utes to allow Neuroporter/DNA complexes to form, and then 
added directly to the HNSCs in a 6-well plate. One day later, 
the media is replaced with fresh growth media; one day later, 
The manimalian expression vector containing Hathl gene 
was transfected into HNSCs by using the Neuroporter Kit 
(Gene Therapy Systems, Inc. San Diego, Calif.) and Hath 1 
gene expression was confirmed by RT-PCR. These Hathl-
transfected HNSCs were differentiated for 7 days by the 
depletion of mitotic factors (FGF-2, EGF) from the culture 
media.Afterthe differentiation the cells were fixed for immu-
nocytochemistry and Electron Microscopy. 
60 this is replaced with differentiation media (Basal Medium 
Eagle) to induce spontaneous differentiation. The cells are 
cultured for 1-2 weeks in a basal differentiation medium 
containing Eagle's salts and L-glutamine, which is not 
supplemented with FGF-2 or EGF, and is serum-free. 
The immunocytochemistry revealed the existence of cells 
expressing calretinin, a hair cell marker, which were immu-
noreactive in this culture. These calretinin immunopositive 
65 RT-PCR 
TRizol reagent is used to extract RNA for RT-PCR and 
protein for a Western Blot. 6 µl of the template RNA is added 
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to 1 x Reaction Mix, 1 µM of each Hathl-specific primer, and 
1 µl of the RT-Platinum® Taq Mix. The total volume of the 
solution is 20 µ!.The RT-PCR condition is 94° C. (15"), 59° 
C. (30"), 72° C. (60") for 40 cycles, with an initial denatur-
ation of 55° C. (30') and 94° C. (5'). 
Immunocytochemistry 
The cells are fixed with 4% paraformaldehyde for 30' at 
room temperature, washed in phosphate-buffered saline 
(PBS, pH 7.2), then blocked with 3% normal goat serum in 
PBS containing 0.05% Triton-XlOO for 1 hour. The cells are 
incubated with primary antibody calretinin overnight at 4 ° C., 
with a dilution factor of (1:2000) in PBS containing 0.05% 
Triton-XlOO. 
Following PBST washing, the cells are incubated with 
secondary antibody biotinylated anti-rabbit made in goat in 
PBS containing 0.05% Triton-XlOO (PBST), with a dilution 
factor of 1 :200. This incubation takes 1 hour. The cells are 
washed with PBST, and incubated with ABC reagent for 1 
hour. Following a PBS wash and staining with DAB for 5-8', 
the cells are washed with PBS and distilled water, then stained 
with methyl green (5'). The cells are washed with water, 
ethanol, and xylene, coverslipped with permount, and ready 
for viewing with microscopy. 
Western Blot 
A Western Blot is performed to assay protein expression. 
The protein is extracted with TRizol reagent. 15 µl of the 
protein is loaded with the size marker on a PVDF membrane 
and run at 200V and 110 mA/gel for 50'. The transfer is run 
overnight at 15\7, 170.0 mA at 4 ° C. The membrane is then 
washed with PBST 2x10' while rotating, and blocked with 
3% milk for 60'. This is washed 2xl 0' with PBST and blocked 
with the primary antibody calretinin (1:500) overnight at 4° 
C. After washing 3x5' with PBST the membrane is incubated 
with the secondary antibody (1 :2000) and shaken for 1 hour. 
For detection, 7.5 mL of ECL solution is warmed to room 
temperature and 187 .5 µl of solution Bis added to solution A. 
7 .5 mL is added to the membrane at RT for 5'. The membrane 
is then placed in an x-ray film cassette and exposed as needed 
for chemilumescent detection. 
Electron Microscopy 
Cells were fixed with 3% glutaraldehyde with cacodyate 
buffer O.lM, and dehydrated with a series of alcohols begin-
ning with 50% up to 100% absolute ethanol followed by 
hexamethyldislazne (HMDS). The cultured cells were 
allowed to air-dry at room temperature. The specimens were 
attached to aluminum stubs using double sided carbon coated 
tape, sputter-coated with Platinum and palladium using the 
Cressington 208 HR High Resolution Coater. Samples were 
viewed with a Jeol 6320F Field Emission Microscope (high 
resolution images) and recorded with a digital camera. 
Samples were also viewed with the Hitachi Variable pressure 
microscope in V-P mode (variable pressure mode) and digi-
tals were captured. 
Results 
A non-serum HNSC culture system was utilized (Christo-
pher L. Brannen and Kiminobu Sugaya, Regeneration and 
Transplantation, 11:5, 1123-1128 (2000)). This culture sys-
tem provides for the differentiation and expansion ofHNSCs 
12 
expressed in stem cells) positive, and GFAP- and ~III-tubu­
lin-negative before differentiation. Upon differentiation, 
various differentiated cells typically express glial fibrillary 
acidic protein (GFAP), or ~III-tubulin, which are glial and 
5 neuronal markers, respectively. 
Preferential differentiation of HNSCs into IEHCs can be 
induced in vitro by the transfection of Hathl. The human 
Hathl gene was amplified from the Homo sapiens BAC clone 
RPl 1-680117 by PCR and cloned into a directional pcDNA-
10 Hismax TOPO TA vector. This was confirmed by sequencing 
of the insert. After confirming expression of the gene by 
RT-PCR, the Neuroporter kit was utilized to tranfect HNSCs. 
These HNSCs were known to be viable and capable of dif-
ferentiation, aggregrating in neurospheres when multipotent. 
15 Once they began the process of differentiation, they left their 
neurospheres. After allowing 7 days for differentiation, these 
cells were either stained for hair cell specific markers or 
assayed for protein expression. Via immunocytochemistry, 
the hair cell marker calretinin was identified on certain cells 
20 (FIG. 2). Via RT-PCR, the expression of this protein XX 
clarify which figure or protein? was also verified (FIG. 3). 
The presence of the actual protein calretinin on the cell 
surface was determined via Western Blot. Seven days for 
differentiation was allowed before any analysis of the cells. 
25 Protein was isolated from the cells and calretinin was identi-
fied in the cell isolate (FIG. 4). 
Using Transmission Electron Microscopy, cells trans-
fected with Hathl and grown to allow for differentiation were 
visualized. A subset of the cells exhibited distinct hair-like 
30 projections. These were the actual hairs from the transfected 
HNSCs that differentiated into cells having this characteristic 
feature ofIEHCs (FIGS. 5 and 6). 
Discussion 
In order to replace damaged IEHCs, a renewable source 
35 must be created. The HNSCs cultured in serum-free medium 
were shown to have the ability to become transfected by 
Hathl and then differentiate in vitro into IEHCs, or cells 
having characteristics of IEHCs. In the present example, 
transfection with and expression of Hathl appears to be an 
40 essential step in the genesis from HNSCs to IEHCs, or cells 
having characteristics of IEHCs. 
Beforetransfection, HNSCs do not express Hathl. Follow-
ing transfection with the Neuroporter Kit, they express this 
gene in their DNA as verified by RT-PCR. They also produce 
45 the hair cell specific marker calretinin as verified by immun-
cytochemistry and Western Blot. Furthermore, actual hairs 
from the transfected cells can be visualized through electron 
microscopy. Thus, characteristics of IEHCs are shown by 
these data, and it appears that these cells either are end-stage 
50 IEHCs or are presumptive IEHC cells in that they have at least 
two characteristics ofIEHCs. 
Cells expressing IEHC markers and differentiating into 
cells with hairlike extremities have been generated in this 
example. These methods, and the cells produced by the meth-
55 ods of the present invention, as shown in this example, 
advance the art of differentiating multipotent stem cells 
toward obtaining end-stage neuron-type cells. 
in vitro in the absence of serum. This system provides for the 
observation of differentiation of HNSCs within a defined 60 
condition. These HNSCs have been cultured in a medium 
consisting of DMEM/F12, antibiotic-antimycotic mixture 
(1:100), B-27 supplement (1:50), human recombinant FGF-2 
and EGF (20 ng/ml each), and heparin (5 µg/ml). These cells 
have been maintained at 37° C. in a 5% C02 humidified 65 
incubation chamber for more than 3 years in the lab. These 
cells are CD133- (a stem cell marker, which is known to be 
EXAMPLE2 
Introduction 
A cholinergic deficit is one of the primary features of 
Alzheimer's disease (AD), where there is a marked degen-
eration oflong-projecting axons of cholinergic neurons in the 
basal forebrain and target areas in the hippocampus and cere-
bral cortex. Recent progress in stem cell technologies sug-
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gests the probability of using neuroreplacement strategies in 
AD therapy, although several hurdles are implicated: i) is it 
possible to generate large numbers of cholinergic neurons 
from stem cells; and ii) can long-projecting cholinergic neu-
rons be replaced? Toward improving the ability to conduct 5 
research in the area of cell implantation and replacement 
therapies, and toward achieving desired results in later-devel-
oped therapies, embodiments of the present invention are 
directed to bias human neural stem cells (HNSCs) to differ-
entiate to cells having characteristics of cholinergic neurons 10 
through genetic manipulation of endogenous neural precur-
trypsin/I mM EDTA (Gibco, BRL) and allowed to attach 
overnight. A fresh stock of 4 mM all-trans retinoic acid RA 
(Sigma, St. Louis, Mo.) was prepared in 100% ethanol under 
amber lighting. RA solution was diluted into culture media 
(final concentration. 10-6M) and we replaced themedia in the 
cells with the RA-containing media. The media was changed 
every 48 h during the differentiation of the cells, which was 
complete after 7-14 days. 
Lhx8 subcloning: The mouse cDNA clone for Lhx8 (SEQ 
ID NO: 7, akindgift from Dr Westphal, NIH, Bethesda, Md.) 
was inserted into the EcoRl site of the pc DNA 3.1/Zeo mam-
malian expression vector (Invitrogen). Insertion was subse-
quently confirmed by restriction digestion and sequence 
analysis. This mouse Lhx8 (SEQ ID NO: 7) has high homol-
sors in situ. 
The LIM-homeobox gene Lhx8 has been reported to be 
crucial for the proper development of basal forebrain cholin-
ergic neurons in mouse (Zhao et al., 2003; Mori et al., 2004). 
Lhx8 is expressed in progenitor and postmitotic cells, sug-
gesting that it may have an important role in specification of 
neural precursor cells and maintenance of phenotype in dif-
ferentiating and mature neurons. Furthermore, previous stud-
ies using the human neuroblastoma cell line, LA-N-2, have 
demonstrated that treatment with retinoic acid (RA) further 
enhances cholinergic characteristics of these cells, thus pro-
viding a good in vitro model of cholinergic neurons (Cro-
sland, 1996). 
The present example utilizes an in vitro assay cell co-
culture model with plated RA-differentiated LA-N-2 cells 
and membrane inserts containing Lhx8-transfected HNSCs, 
to assess whether the Lhx8-transfected HNSCs adopt a cho-
linergic neuronal fate. The rationale behind this co-culture 
model is that HNSCs are influenced by intrinsic as well as 
extracellular factors in the microenvironment and therefore, 
able to respond by differentiating into specific cell types 
according to the environmental cues to which they are 
exposed. Culture ofRA-diff erentiated LA-N-2 in basal media 
under a serum-free condition, results in the release of factors 
to the Lhx8-transfected HNSCs in co-culture. It should be 
noted that there is no cell-to-cell contact in this co-culture 
system. Thus it is reasonable to assume that any modification 
of the cell fate of the genetically modified HNSCs by the 
cholinergic-differentiated LA-N-2 cells would come from 
membrane permeable endogenous factor(s) released from the 
cholinergic-differentiated LA-N-2 cells. 
Materials & Method 
15 ogy to the human sequence (70-80%). 
Transfection: HNSCs were placed in 6-well poly-lysine 
coated plates and transfected with 4 µg pcDNA 3.1/Lhx8 
plasmid using the Neuroporter transfection system (Gene 
Therapy Systems, see description in Example 1 ). Upon the 
20 insertion of the Lhx8 gene expressible sequence into the 
directional cloning vector, the expressible sequence was 
operatively linked to the CMV promoter, and was also posi-
tioned upstream (with regard to reading) ofa polyadenylation 
transcription termination site. Lhx8 expression was con-
25 firmed after 48 hrs by RT-PCR using primers designed from 
the gene cDNA sequence; 5'TGCTGGCATGTCCGCT-
GTCT' 3 (SEQ ID NO: 12, upper primer) and 5'CTG-
GCTTTGGATGATTGACG'3 (SEQ ID NO: 13, lower 
primer). To initiate differentiation, HNSCs were placed in 
30 serum-free basal medium, and allowed to differentiate for 
10-15 days in culture. 
Co-cultures oftransfected HNSCs and RA-treated LA-N-2 
cells: HNSCs (-5xl04 ) transfected with pcDNA 3.1/Lhx8 
and non-transfected HNSCs (controls) were transferred into 
35 cell culture inserts with an appropriate pore size and sus-
pended in basal media (in the absence ofFGF-2 and EGF and 
without the addition of other extrinsic differentiation factors) 
over differentiated LA-N-2 cells plated in 6-well plates. For 
immunocytochemical analyses of HNSCs, the culture insert 
40 was removed after 10-20 days of co-culture and the HNSCs 
were fixed with 4% paraformaldehyde overnight at 4° C. 
Also, transfected HNSCs were cultured without the presence 
of differentiated LA-N-2 cells to assess the need for and 
HNSCs culture: Human NSCs were originally purchased 
from Bio Whittaker, Walkersville, Md. These cells have been 45 
expanded and passaged in a serum-free culture medium con-
taining bFGF and EGF in our laboratory for over three years 
(Brannen & Sugaya, 2000). The HNSCs were cultured at a 
density of50 spheres in 75 cm2 culture flasks (Corning, Cam-
bridge, Mass.) in 20 ml of a serum-free supplemented growth 50 
medium consisting ofHAMS-F12 (Gibco, BRL, Burlington, 
ON), antibiotic-antimycotic mixture (1: 100, Gibco ), B27 
effectiveness of the co-culturing. 
Immunocytochemistry: 
Following fixation, HNSCs were briefly washed 3x5 min 
in Phosphate buffered saline (PBS), then blocked with 3% 
normal donkey serum in PBS containing 0.05% Tween 20 
(PBS-T) and incubated with goat IgG polyclonal anti-human 
ChAT (1 :500, Chemicon), mouseigG2b monoclonal anti-hu-
man ~III-tubulin (1:1000, Sigma) or rabbit anti-human glial 
filament protein (GFAP) (1:1000, Sigma) overnight at 4° C. 
The corresponding secondary antibodies (donkey anti-goat, 
donkey anti-mouse, and donkey anti-rabbit, respectively) 
conjugated to rhodamine or FITC (Jackson IR Laboratories, 
Inc.) were added for a 2 hr incubation at RT in the dark. Cells 
(1: 50, Gibco ), human recombinant FGF-2 and EGF (20 ng/ml 
each, R&D Systems, Minneapolis, Minn.) and heparin (5 
µg/ml, Sigma, St. Louis, Mo.) incubated at 37° C. in a 5% 55 
C02 humidified incubation chamber (Fisher, Pittsburg, Pa.). 
To facilitate optimal growth conditions, HNSCs were sec-
tioned into quarters every 2 weeks and fed by replacing 50% 
of the medium every 4-5 days. 
LA-N-2 humanneuroblastomaculture: LA-N-2 cells were 60 
were then washed with PBS (3x5 min) and mounted with 
Vectashield with DAPI (Vector Laboratories, Calif.) for fluo-
rescent microscopic observation. LA-N-2 cells were simi-
larly treated to prepare for microscopic observations. 
obtained from Dr. Jan Blusztajn (Boston University, Mass.). 
The cells were cultured in Leibovitz L-15 medium (Gibco, 
BRL, Burlington, ON) containing 10% fetal calf serum and 
antibiotic-antimyotic mixture (Gibco) in a humidified incu-
bator at 3 7° C. without C02. The medium was replaced every 
3 days. For treatment with retinoic acid (RA), the cells were 
sub-plated at a density of0.5-lxl06 cells/plate using 0.25% 
Results 
LA-N-2 cells treated with RA expressed Lhx8, ~III-tubu­
lin, and ChAT. This is demonstrated in FI GS. 7 A-D. FIG. 7 A 
shows LA-N-2 cells stained red indicating the presence of 
65 ~III-tubulin. FIG. 7B shows LA-N-2 cells stained green indi-
cating the presence of ChAT. FIG. 7C shows LA-N-2 cells 
stained green indicating the presence of NGF (blue stain 
US 8,513,017 B2 
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indicating counter-staining for nuclei by DAPI). FIG. 7D 
(insert) shows non-specific staining for ChAT. 
16 
In vitro, HNSCs expressing the LIM homeobox gene, 
Lhx8, differentiated into mainly ~III-tubulin and ChAT-posi-
tive cells, in co-culture with LA-N-2 cholinergic cells. For the 
transfected HNSCs cultured without the presence of differ-
entiated LA-N-2 cells, there was no significant difference 
from the non-transfected HNSCs with regard to the number of 
cells differentiating to cells having characteristics of chol-
ingeric cells. This demonstrated the need under these experi- 10 
mental conditions for the differentiated LA-N-2 cells (and the 
factors released by them). 
transfected gene, or may be other factors known in the art or 
later determined to be useful in achieving a desired differen-
tiation. 
Also, it is appreciated that multipotent stem cells may be 
cultured without an accessory cell, and may receive factors by 
direct addition of factors to the culture medium, or such 
factors may be released by cells at a site of implantation, or 
may be added to a site of implantation. 
EXAMPLE3 
Using the same vector formation and transfection methods 
as in Example 2, the Human Lxh8 gene (SEQ ID NO: 6) is 
transfected into HNSCs. Transfected NHSC cells are cultured 
Non-transfected HNSCs differentiated into mainly ~III­
tubulin and GFAP positive cells in co-culture with LA-N-2 
cholinergic cells. 
With regard to percentage differences between non-trans-
fected cells and transfected cells, in one trial less than two 
percent of non-transfected cells, and over 40 percent oftrans-
fected cells, were observed at the end of the trial to have 
characteristics of cholinergic neurons. 
CONCLUSIONS AND COMMENTS 
Expression of the LIM-homeobox gene Lhx8 triggers 
HNSCs to adopt a cholinergic neural lineage. Cells having the 
noted characteristics of cholinergic neurons either are cholin-
ergic neurons or presumptive cholinergic neurons in that they 
have at least two characteristics of cholinergic neurons. 
LA-N-2 cells in co-culture with HNSCs expressing Lhx8, 
suggest that the microenvironment is also important for the 
differentiation and survival of cholinergic neurons. 
15 in a first treatment that includes LA-N-2 cells that are treated 
with RA and that express both Lhx8 and ChAT. A co-culture 
control comprises NHSCs that are not transfected but that are 
in the same culture vessel as LA-N-2 that are treated with RA 
20 and that express both Lhx8 and ChAT. For the first treatment 
and the co-culture control, HNSC cells are placed in cell 
culture inserts with an appropriate pore size and suspended in 
basal media (in the absence ofFGF-2 and EGF and without 
the addition of other extrinsic differentiation factors) over 
25 differentiated LA-N-2 cells plated in 6-well plates. 
Immunochemistry follows the same procedure as m 
Example 2 above. 
Results indicate that HNSCs transfected with the Human 
Lxh8 gene (SEQ ID NO: 6) also are predisposed, or biased, to 
30 differentiate into cells that have characteristics of cholinergic 
neurons. Observable results include cells that are positive for 
~III-tubulin and ChAT. The present invention may provide utility by biasing 
human neural stem cells through genetically manipulation so 
that the cells so manipulated may be used in research, includ-
ing as cells transplantable, such as in experiments, and thera- 35 
pies, including regarding replacing damaged cholinergic neu-
EXAMPLE4 
An additional development control gene, Gbxl sequence 
(SEQ ID NO: 9), is transfected into HNSCs and is evaluated 
as to its capacity to bias HNSCs to differentiate to cholingeric 
cells, or to cells having characteristics of cholinergic cells. 
rans. 
As to the efficiency of biasing to a desired cell type, and to 
observing cells having characteristics of a desired end-stage 
cell type, without being bound to a particular theory, it is 
believed that the factors that increase the efficiency of biasing 
by transfection include: 1) inherent properties of the cell to be 
transfected; 2) inherent efficiency of the selected vector or 
method of transfection; 3) relative percentage of cells in 
which the introduced nucleic acid sequence enters the 
nucleus compared to remains in the cytoplasm; and 4) number 
of copies of the nucleic acid sequence that are available for 
expression in the cell. Methods of transfection are well-
known in the art, and the use and modification of known 
approaches to transfection of a cell with a nucleic acid 
sequence to be expressed therein to improve the percentage of 
biasing are within the scope of the present invention. 
Thus, it is appreciated that in some embodiments of the 
present invention, a multipotent stem cell is transfected with 
40 The Gbxl cDNA sequence (SEQ ID NO: 9) is inserted into 
the enhanced green fluorescent protein (EGFP) vector 
pEGFP-Cl ((BDBiosciences Clontech) at the EcoRl site 
within the vector's multiple cloning site, which is 3' ofa CMV 
promoter and the EGFP gene (See FIG. 8; sequence disclosed 
45 as SEQ ID NO: 17). Further, in that a question remains as to 
whether the percentage of biasing is related directly to the 
percentage of transfection of cells in population of cells 
exposed to a transfecting vector, the human Lhx8 cDNA 
(SEQ ID N0:6) independently also is inserted into a second 
50 pEGFP-Cl vector. This allows for visualization of both vec-
tors, each bearing an expressible sequence for a different 
developmental control gene, in cells in respective cell popu-
lations into which these vectors are transfected. 
a desired developmental control gene, and the expression of 55 
the gene during in vitro culture biases the differentiation of 
that cell to a desired end-stage differentiated cell. In other 
embodiments, the multi potent stem cell may be transfected in 
vivo with a developmental control gene whose expression 
biases transfected cells to differentiate into a desired end- 60 
Culture methods of the HNSCs into which the Gbxl and 
the Lhx8 genes are transfected are as described above in 
Example 2. 
This experiment provides an estimate of the ratio of 
HNSCs that become cholinergic neurons based on percent 
transfected of the population. Compared to non-transfected 
control HNSCs, the transfected cells have characteristics of 
the desired end-stage differentiated cell type, that is, a cho-stage cell. In any of such embodiments, accessory cells may 
provide factors that are needed for, or that assist with, the 
differentiation of the transfected cell. These accessory cells, 
such as the co-cultured LA-N-2 cells in the above example, 
need not be in contact with the transfected cells, demonstrat-
ing here that the factors are membrane permeable. These 
factors may include the same factor that is expressed by the 
linergic neuron. 
This demonstrates that a number of development control 
genes, particularly transcription factor genes, may be intro-
65 duced into a HNSC to bias that cell (or its progeny) to differ-
entiate to a cell having the characteristics of a desired end-
stage differentiated neural cell type. 
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EXAMPLES 
Cell sorting technology is combined with the above-de-
scribed embodiments of the present invention, particularly 
the vectors of Example 4, to improve the yield and selection 
18 
temperature is used to define the required stringency condi-
tions. If sequences are to be identified that are related and 
substantially identical to the probe, rather than identical, then 
it is useful to first establish the lowest temperature at which 
only homologous hybridization occurs with a particular con-
centration of salt (e.g., SSC or SSPE). 
Then, assuming that 1 % mismatching results in a 1 ° C. 
decrease in the Tm, the temperature of the final wash in the 
hybridization reaction is reduced accordingly (for example, if 
of desired cells having the bias to differentiate to a desired 
end-stage cell (or having already so differentiated). For 
example, not to be limiting, the introduction of genetic mark-
ing such as described above, using EFGP, and the use of 
Fluorescent Activated Cell Sorter (FACS) techniques is uti-
lized to sort and select cells that have been transfected with 
the desired developmental control gene (which is linked to a 
marker on the vector). The FACS technology is well known in 
the art (See, for example, U.S. patent application number 
2002/0127715 Al.) 
10 sequences having >95% identity with the probe are sought, 
the final wash temperature is decreased by 5° C.). In practice, 
the change in Tm can be between 0.5° C. and 1.5° C. per 1 % 
mismatch. Stringent conditions involve hybridizing at 68° C. 
in 5xSSC/5xDenhardt's solution/1.0% SDS, and washing in 
Using FACS, HNSCs that are transfected with a vector 
bearing both EFGP and either Gbxl or Lhx8 are sorted and 
thereby concentrated. This adds to the utility and effective-
ness of the biasing by reducing the number and percentage of 
cells that are not transfected. 
15 0.2xSSC/0.1 % SDS at room temperature. Moderately strin-
gent conditions include washing in 3xSSC at 42° C. The 
parameters of salt concentration and temperature can be var-
ied to achieve the optimal level of identity between the probe 
and the target nucleic acid. Additional guidance regarding 
20 such conditions is readily available in the art, for example, by 
Sambrook et al., 1989, Molecular Cloning, A Laboratory 
Manual, Cold Spring Harbor Press, N.Y.; andAusubel et al. 
(eds), 1995, Current Protocols in Molecular Biology, (John 
The above examples utilize specific sequences of genes 
incorporated into respective vectors and introduced into 
HNSCs. However, the present invention is not meant to be 
limited to the specifics of these examples. First, in addition to 
Math!, Hath!, Lxh8 and Gbxl, other developmental control 25 
genes of interest include Lhx6, IsLl, Dlxl/2 and Mash. 
Examples of cDNA sequences, and corresponding translated 
polypeptide and protein sequences, of these and other devel-
opmental control genes are readily obtainable from the Gen-
Bank online database (See ncbi.nlm.nih.gov/entrez/ 
query.fcgi.), and these are hereby incorporated by reference 
for that purpose. 
Wiley & Sons, N.Y.) at Unit 2.10. 
The above-specified sequences are not meant to be limit-
ing. For example, provided herein are additional identified 
sequences for Math! (SEQ ID Nos:2 and3), and Hath! (SEQ 
ID N0:5). Numerous other similar sequences are known and 
searchable at GenBank. Also, the methods and compositions 
30 disclosed and claimed herein for other sequences may be 
practiced with Gbxl (SEQ ID N0:9) and sequences similar to 
Also, as to the nucleic acid sequences comprising the genes 
of interest, specific sequences of which are provided in the 
above examples and in the above paragraph, it is appreciated 35 
that substantial variation may exist in a nucleic acid sequence 
for a gene, yet a polypeptide or protein may nonetheless be 
produced in a cell from one of a number of such variant 
nucleic acid sequences, wherein such polypeptide or protein 
has a desired effect on the cell comparable to a polypeptide or 40 
protein produced from one of the nucleic acid sequences 
specified in the above examples. That is, variations may exist 
it. 
Further, the sequences for introduced genes and polypep-
tides or proteins expressed by them may also be defined in 
terms of homology to one of the sequences provided in the 
above examples and discussion. In the context of the present 
application, a nucleic acid sequence is "homologous" with 
the sequence according to the invention if at least 70%, pref-
erably at least 80%, most preferably at least 90% of its base 
composition and base sequence corresponds to the sequence 
specified according to the invention. According to the inven-
tion, a "homologous protein" is to be understood to comprise 
proteins which contain an amino acid sequence at least 70% 
of which, preferably at least 80% of which, most preferably at 
in a nucleic acid sequence for a gene yet the variations none-
theless function effectively when substituted for a nucleic 
acid sequence of a specified gene. 
Accordingly, embodiments of the present invention also 
include and/or employ nucleic acid sequences that hybridize 
under stringent hybridization conditions (as defined herein) 
45 least 90% of which, corresponds to the amino acid sequence 
disclosed in (Gish and States, 1993); wherein corresponds is 
to be understood to mean that the corresponding amino acids 
are either identical or are mutually homologous amino acids. 
to all or a portion of a nucleic acid sequence represented by 
any of the SEQ ID Nos. 1-13, or their complements, or to 50 
sequences forlsLl, Dlxl/2, Mash, or their complements. The 
hybridizing portion of the hybridizing nucleic acid sequences 
is typically at least 15 (e.g., 20, 25, 30, or 50) nucleic acids in 
length. The hybridizing portion of the hybridizing nucleic 
acid sequence is at least 80%, e.g., at least 95%, or at least 55 
98%, identical to the sequence of a portion or all of a nucleic 
acid sequence encoding one of genes identified by the noted 
Sequence ID numbers, or one of their complements. Hybrid-
izing nucleic acids of the type described herein can be used, 
for example, as a cloning pro be, a primer (e.g., a PCR primer), 60 
or a diagnostic probe, as well as for a gene transfected into a 
cell as described in the examples above. 
Hybridization of the oligonucleic acid probe to a nucleic 
acid sample typically is performed under stringent condi-
tions. Nucleic acid duplex or hybrid stability is expressed as 65 
the melting temperature or Tm, which is the temperature at 
which a probe dissociates from a target DNA. This melting 
The expression "homologous amino acids" denotes those 
which have corresponding properties, particularly with 
regard to their charge, hydrophobic character, steric proper-
ties, etc. Thus, a protein may be from 70% up to less than 
100% homologous to any one of the proteins expressed by 
one of the disclosed introduced genes. 
Homology, sequence similarity or sequence identity of 
nucleic acid or amino acid sequences may be determined 
conventionally by using known software or computer pro-
grams such as the BestFit or Gap pairwise comparison pro-
grams (GCG Wisconsin Package, Genetics Computer Group, 
575 Science Drive, Madison, Wis. 53711). BestFit uses the 
local homology algorithm of Smith and Waterman, Advances 
in Applied Mathematics 2: 482-489 (1981 ), to find the best 
segment of identity or similarity between two sequences. Gap 
performs global alignments: all of one sequence with all of 
another similar sequence using the method ofNeedleman and 
Wunsch, J. Mo!. Biol. 48:443-453 (1970). When using a 
sequence alignment program such as BestFit, to determine 
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the degree of sequence homology, similarity or identity, the 
default setting may be used, or an appropriate scoring matrix 
may be selected to optimize identity, similarity or homology 
scores. Similarly, when using a program such as BestFit to 
determine sequence identity, similarity or homology between 
two different amino acid sequences, the default settings may 
be used, or an appropriate scoring matrix, such as blosum45 
or blosum80, may be selected to optimize identity, similarity 
or homology scores. 
Alternatively, as used herein, "percent homology" of two 10 
amino acid sequences or of two nucleic acids is determined 
using the algorithm of Karlin andAltschul (Proc. Natl. Acad. 
Sci. USA 87:2264-2268, 1990), modified as in Karlin and 
Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993). 
Such an algorithm is incorporated into the NBLAST and 15 
XBLAST programs of Altschul et al. (J. Mo!. Biol. 215:403-
410, 1990). BLAST nucleic acid searches are performed with 
the NB LAST program, score= 100, wordlength= 12, to obtain 
nucleic acid sequences homologous to a nucleic acid mol-
ecule of the invention. BLAST protein searches are per- 20 
formed with the XBLAST program, score=50, 
wordlength=3, to obtain amino acid sequences homologous 
to a reference polypeptide. To obtain gapped alignments for 
comparison purposes, Gapped BLAST is utilized as 
described in Altschul et al. (Nucleic Acids Res. 25:3389- 25 
3402, 1997). When utilizing BLAST and Gapped BLAST 
programs, the default parameters of the respective programs 
(e.g., XBLAST and NBLAST) are used. See ncbi.nlm. 
nih.gov. 
Further, in addition to the homology, as indicated in certain 30 
claims (i.e., for some embodiments), is a requirement that the 
homologous or hybridizable nucleic acid sequence or 
polypeptide or protein functions analogously to the specified 
sequence of which it is homologous or with which it is hybrid-
izable. That is, the homologous or hybridizable variant func- 35 
tions to achieve the same result, i.e., to increase the probabil-
ity of a transfected cell, or the percentage of a number of cells, 
that are biased to differentiate to a cell, or cells, respectively, 
having characteristics of a desired end-stage differentiated 
cell. 40 
20 
exceeds 40 percent, in other embodiments the percentage of 
transfected cells biased exceeds 50 percent, in other embodi-
ments the percentage of transfected cells biased exceeds 65 
percent, and in other embodiments the percentage of trans-
fected cells biased exceeds 70 percent. However, it also is 
appreciated that determination of the percentage of cells that 
are in fact transfected in a given container of cells may be 
difficult to assess, the performance of the present invention in 
certain embodiments may be expressed in an alternative man-
ner. That is, in some embodiments of the present invention in 
which a number of cells has been exposed to a selected 
method or means of transfection for the purpose of introduc-
ing a desired developmental control gene (such as Lhx8), the 
percentage of total cells that are biased to a desired end-stage 
cell type, or to a cell having characteristics of a desired end-
stage cell type, is at least 35 percent, in other embodiments 
such percentage of total cells exceeds 50 percent, and in other 
embodiments such percentage of total cells exceeds 70 per-
cent. 
Further, it is appreciated that embodiments of the present 
invention are described as follows: 
1. A neural stem cell, including a human neural stem cell, 
comprising an introduced nucleic acid sequence having 
an expressible developmental control gene, the expres-
sion of said gene being effective to increase the prob-
ability of differentiation of said cell to a desired neural 
cell type. 
2. A neural stem cell, including a human neural stem cell, 
comprising an introduced nucleic acid sequence having 
an expressible developmental control gene, the expres-
sion of said gene being effective to increase the prob-
ability of differentiation of said cell to a cell having 
characteristics of a cholinergic neuron. 
3. A neural stem cell, including a human neural stem cell, 
comprising an introduced nucleic acid sequence having 
an expressible developmental control gene, the expres-
sion of said gene being effective to increase the prob-
ability of differentiation of said cell to a cell having 
characteristics of an inner ear hair cell. 
4. A neural stem cell, including a human neural stem cell, 
comprising an introduced nucleic acid sequence having 
an expressible developmental control gene, the expres-
sion of said gene being effective to increase the prob-
ability of differentiation of said cell to a cell having 
characteristics of a dopaminergic neuron. 
The developmental control gene in the above first descrip-
tion of embodiments of the present invention may be selected 
from the group consisting of Math!, Hath!, Lhx8, Gbxl, 
Lhx6, IsLl, Dlxl/2, Mash and Nurrl. The developmental 
While the transfection into HNSCs in the above examples 
uses the Neuroporter approach (Gene Therapy Systems, Inc. 
San Diego, Calif.), it is appreciated that any known or later-
developed method of introduction of a nucleic acid sequence 
may be employed in the methods and systems, and to produce 45 
the compositions, of the present invention. For example, and 
not to be limiting, introduction of a nucleic acid sequence 
may be effectuated by stable or transient transfection, lipo-
fection by methods other than Neuroporter, calcium phos-
phate treatment, electroporation, infection with a recombi-
nant viral vector, and the use of vectors comprising a plasmid 
construct. Generally and collectively, these methods are con-
sidered to be included in the term "means to transfect," in the 
term "step for transfecting."Also, the use of the particular 
promoter and polyadenylation transcription termination site 
are not meant to be limiting, as many promoter and transcrip-
tion termination sites are known and used routinely in the art. 
50 control gene in the above second description of embodiments 
of the present invention may be selected from the group 
consisting ofLhx8, Gbxl, Lhx6, IsLl, Dlxl/2, and Mash. The 
developmental control gene in the above third description of 
embodiments of the present invention may be selected from 
As to the use of different means to transfect, and in view of 
the above discussion of the relative percentage of cells biased 
to cells having characteristics of a desired end-stage cell type, 
it is appreciated that types of transfection, cells that are trans-
fected, and other factors, including post transfection condi-
tions, affect the percentage of cells ultimately biased. In view 
of these factors, and considering the importance of the spe-
cific developmental control genes that are introduced to a cell 
in certain embodiments of the present invention, in some 
embodiments the percentage of transfected cells biased 
55 the group consisting of Math! and Hath!. Finally, the devel-
opmental control gene in the above fourth description of 
embodiments of the present invention may be Nurrl, Pitx3 
(SEQ ID NO: 13) or other later-identified specific genes. 
Also, it is appreciated that the present invention, particu-
60 larly for the genes Math!, Hath!, Lhx8, Gbxl, Lhx6, IsLl, 
Dlxl/2, and Mash, may be utilized in potent cells, that is, in 
cells that are considered to fall within the definitions of pluri-
potent, of multipotent, and of progenitor cells (i.e., more 
differentiated than multipotent yet capable of limited self-
65 renewal). 
Based on the above examples and disclosure, in view of the 
knowledge and skill in the art, it also is appreciated that 
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embodiments of the present invention also are used for any 
homeobox gene, so that a homeobox gene is transfected to a 
stem cell to effect a biasing of the stem cell to differentiate to 
a desired end-stage cell, or to a cell having characteristics of 
the end-stage cell. The stem cell may be a pluripotent or a 
multipotent stem cell; alternatively invention embodiments 
transfecting homeobox genes may be practiced with progeni-
tor cells as described herein. Cells so biased by these genes 
following the methods of the present invention also are con-
sidered to fall within the scope of embodiments of the present 
invention. 
EXAMPLE6 
Nkx.2-5 Biases the Differentiation Toward the 
Development of Cardiac Cells 
According to another embodiment, transfection with 
Nkx2-5 (SEQ ID NO: 12) biases the differentiation toward 
the development of cardiac cells. See FIG. 17. Red=human 
specific Troponin I, Green= Human cells. Following transfec-
tion, multipotent stem cells were cocultured with rat cardi-
omyocytes that provide environmental signals to allow the 
transfected cells to develop properly. 
22 
by virtue of initiating differentiation (or being less self-re-
newing) may by some opinions therefore not be considered to 
be multipotent cells. For the purposes ofthis invention, such 
daughter cells, which may be found in culture with the mul-
tipotent stem cells from which they arose, are termed "bias-
able progeny cells." 
It is appreciated that embodiments of the present invention 
also may be defined and claimed with regard to the polypep-
tide or protein sequences expressed as a result of the trans-
10 fections disclosed and discussed above. For example, not to 
be limiting, the peptide sequences, disclosed as the transla-
tion sequences in the attached Sequence Listing pages, and 
their expression in a transfected cell, are used to identify 
and/or characterize a characteristic and/or result of embodi-
15 ments of the present invention. Translation sequences are 
obtainable from the respective GenBank database data entries 
for cDNAs as described herein, and those database entries are 
incorporated by reference for such information. 
While a number of embodiments of the present invention 
20 have been shown and described herein in the present context, 
such embodiments are provided by way of example only, and 
not of limitation. Numerous variations, changes and substi-
tutions will occur to those of skilled in the art without mate-
rially departing from the invention herein. For example, the 
present invention need not be limited to best mode disclosed 
herein, since other applications can equally benefit from the 
teachings of the present invention. Also, in the claims, means-
plus-function and step-plus-function clauses are intended to 
cover the structures and acts, respectively, described herein as 
Further, and more generally, embodiments of the present 25 
invention may be practiced by transfecting a stem or a pro-
genitor cell with a nucleic acid sequence comprising a devel-
opment control gene, so that the transfecting is effective to 
bias the cell to differentiate to a desired end-stage cell, or to a 
cell having characteristics of the end-stage cell. 30 performing the recited function and not only structural 
equivalents or act equivalents, but also equivalent structures 
or equivalent acts, respectively. Accordingly, all such modi-
fications are intended to be included within the scope of this 
invention as defined in the following claims, in accordance 
with relevant law as to their interpretation. 
Also, it is appreciated that the methods of the present 
invention may be applied to the daughter cells of multi potent 
cells, which may have begun some stages of differentiation 
but are still capable of being biased by transfection of appro-
priate developmental control genes as described herein, but 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 23 
<210> SEQ ID NO 1 
<211> LENGTH, 2144 
<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 1 
tcgacccacg cgtccgccca cgcgtccgga tctccgagtg agagggggag 
ggaaggaaaa aaaaatcaga ccttgcagaa gagactagga aggtttttgt 
cggggcttat ccccttcgtt gaactgggtt gccagcacct cctctaacac 
agccattgca gtgcgatgtc ccgcctgctg catgcagaag agtgggctga 
ttgggggacc accatcgcca tccccagccg caccacgtcc cgccgctgac 
cctgctaccc tgcaggcgag agaccttccc gt ct ace egg cagaactgtc 
agcaccgacc cacgcgcctg gctgactccc actttgcagg gcctctgcac 
gcccagtatc tgctgcattc tcccgagctg ggtgcctccg aggccgcggc 
gaggctgaca gccagggtga gctggtaagg agaagcggct gtggcggcct 
cccgggcccg tcaaagtacg ggaacagctg tgcaagctga agggtggggt 
gagcttggct gcagccgcca gcgagcccct tccagcaaac aggtgaatgg 
caaaggaggc tggcagcaaa cgcaagggaa cggcgcagga tgcacgggct 
ggtcagagga 60 
tgttgttgtt 120 
ggcacctccg 180 
ggtaaaagag 240 
gccacagcca 300 
cctcctggat 360 
ggcacgcgcc 420 
gccccgggac 480 
cagcaagagc 540 
tgtagtggac 600 
ggtacagaag 660 
gaaccacgcc 720 
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ttcgaccagc tgcgcaacgt tatcccgtcc ttcaacaacg acaagaagct gtccaaatat 
gagaccctac agatggccca gatctacatc aacgctctgt cggagttgct gcagactccc 
aatgtcggag agcaaccgcc gccgcccaca gcttcctgca aaaatgacca ccatcacctt 
cgcaccgcct cctcctatga aggaggtgcg ggcgcctctg cggtagctgg ggctcagcca 
gccccgggag ggggcccgag acctaccccg cccgggcctt gccggactcg cttctcaggc 
ccagcttcct ctgggggtta ctcggtgcag ctggacgctt tgcacttccc agccttcgag 
gacagggccc taacagcgat gatggcacag aaggacctgt cgccttcgct gcccgggggc 
atcctgcagc ctgtacagga ggacaacagc aaaacatctc ccagatccca cagaagtgac 
ggagagtttt ccccccactc tcattacagt gactctgatg aggccagtta ggaaggcaac 
agctccctga aaactgagac aaccaaatgc ccttcctagc gcgcgggaag ccccgtgaca 
aatatccctg caccctttaa tttttggtct gtggtgatcg ttgttagcaa cgacttgact 
tcggacggct gcagctcttc caatcccctt cctcctacct tctccttcct ctgtatgtag 
atactgtatc attatatgta cctttacgtg gcatcgtttc atggtccatg ctgccaatat 
gctgctaaaa tgtcgtatct ctgcctctgg tctgggtttc acttatttta taccttggga 
gttcatcctt gcgtgttgcg ctcactcaca aataagggag ttagtcaatg aagttgtttc 
cccaactgct tgagacccgc attgggtact ttactgaaca cggactattg tgttgttaaa 
atgcaggggc agataagagt atctgtagag cttagacacc aagtgtgtcc agcagtgtgt 
ctagcggacc cagaatacac gcacttcatc actggccgct gcgccgcctt gaagaaactc 
aactgccaat gcagagcaac ttttgatttt aaaaacagcc actcataatc attaaactct 
ttgcaaatgt ttgtttttgc aaatgaaaat taaaaaaaaa catgtagtgt caaaggcatt 
tggtcaattt tattttgctt tgttaacatt agaaaagtta tttattattg cgtatttgga 
cccatttcta cttaattgcc ttttttttac attttctact cgagatcgtt ttattttgat 
ttagcaaatc cagttgccat tgctttatgt atgtatgctc ttttacaaat gataaaataa 
actcggaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 
<210> SEQ ID NO 2 
<211> LENGTH, 2118 
<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 2 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1740 
1800 
1860 
1920 
1980 
2040 
2100 
2144 
acctggtgtg cgatctccga gtgagagggg gagggtcaga ggaggaagga aaaaaaatca 60 
gaccttgcag aagagactag gaaggttttt gttgttgttg ttcggggctt atccccttcg 120 
ttgaactggg ttgccagcac ctcctctaac acggcacctc cgagccattg cagtgcgatg 180 
tcccgcctgc tgcatgcaga agagtgggct gaggtaaaag agttggggga ccaccatcgc 240 
catccccagc cgcaccacgt cccgccgctg acgccacagc cacctgctac cctgcaggcg 300 
agagaccttc ccgtctaccc ggcagaactg tccctcctgg atagcaccga cccacgcgcc 360 
tggctgactc ccactttgca gggcctctgc acggcacgcg ccgcccagta tctgctgcat 420 
tctcccgagc tgggtgcctc cgaggccgcg gcgccccggg acgaggctga cagccagggt 480 
gagctggtaa ggagaagcgg ctgtggcggc ctcagcaaga gccccgggcc cgtcaaagta 540 
cgggaacagc tgtgcaagct gaagggtggg gttgtagtgg acgagcttgg ctgcagccgc 600 
cagcgagccc cttccagcaa acaggtgaat ggggtacaga agcaaaggag gctggcagca 660 
aacgcaaggg aacggcgcag gatgcacggg ctgaaccacg ccttcgacca gctgcgcaac 720 
24 
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gttatcccgt ccttcaacaa cgacaagaag ctgtccaaat atgagaccct acagatggcc 
cagatctaca tcaacgctct gtcggagttg ctgcagactc ccaatgtcgg agagcaaccg 
ccgccgccca cagcttcctg caaaaatgac caccatcacc ttcgcaccgc ctcctcctat 
gaaggaggtg cgggcgcctc tgcggtagct ggggctcagc cagccccggg agggggcccg 
agacctaccc cgcccgggcc ttgccggact cgcttctcag gcccagcttc ctctgggggt 
tactcggtgc agctggacgc tttgcacttc ccagccttcg aggacagggc cctaacagcg 
atgatggcac agaaggacct gtcgccttcg ctgcccgggg gcatcctgca gcctgtacag 
gaggacaaca gcaaaacatc tcccagatcc cacagaagtg acggagagtt ttccccccac 
tctcattaca gtgactctga tgaggccagt taggaaggca acagctccct gaaaactgag 
acaaccaaat gcccttccta gcgcgcggga agccccgtga caaatatccc tgcacccttt 
aatttttggt ctgtggtgat cgttgttagc aacgacttga cttcggacgg ctgcagctct 
tccaatcccc ttcctcctac cttctccttc ctctgtatgt agatactgta tcattatatg 
tacctttacg tggcatcgtt tcatggtcca tgctgccaat atgctgctaa aatgtcgtat 
ctctgcctct ggtctgggtt tcacttattt tataccttgg gagttcatcc ttgcgtgttg 
cgctcactca caaataaggg agttagtcaa tgaagttgtt tccccaactg cttgagaccc 
gcattgggta ctttactgaa cacggactat tgtgttgtta aaatgcaggg gcagataaga 
gtatctgtag agcttagaca ccaagtgtgt ccagcagtgt gtctagcgga cccagaatac 
acgcacttca tcactggccg ctgcgccgcc ttgaagaaac tcaactgcca atgcagagca 
acttttgatt ttaaaaacag ccactcataa tcattaaact ctttgcaaat gtttgttttt 
gcaaatgaaa attaaaaaaa aacatgtagt gtcaaaggca tttggtcaat tttattttgc 
tttgttaaca ttagaaaagt tatttattat tgcgtatttg gacccatttc tacttaattg 
cctttttttt acattttcta ctcgagatcg ttttattttg atttagcaaa tccagttgcc 
attgctttat gtatgtatgc tcttttacaa atgataaaat aaactcggaa aaaaaaaaaa 
aaaaaaaaaa aaaaaaaa 
<210> SEQ ID NO 3 
<211> LENGTH, 2144 
<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 3 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1740 
1800 
1860 
1920 
1980 
2040 
2100 
2118 
tcgacccacg cgtccgccca cgcgtccgga tctccgagtg agagggggag ggtcagagga 60 
ggaaggaaaa aaaaatcaga ccttgcagaa gagactagga aggtttttgt tgttgttgtt 120 
cggggcttat ccccttcgtt gaactgggtt gccagcacct cctctaacac ggcacctccg 180 
agccattgca gtgcgatgtc ccgcctgctg catgcagaag agtgggctga ggtaaaagag 240 
ttgggggacc accatcgcca tccccagccg caccacgtcc cgccgctgac gccacagcca 300 
cctgctaccc tgcaggcgag agaccttccc gtctacccgg cagaactgtc cctcctggat 360 
agcaccgacc cacgcgcctg gctgactccc actttgcagg gcctctgcac ggcacgcgcc 420 
gcccagtatc tgctgcattc tcccgagctg ggtgcctccg aggccgcggc gccccgggac 480 
gaggctgaca gccagggtga gctggtaagg agaagcggct gtggcggcct cagcaagagc 540 
cccgggcccg tcaaagtacg ggaacagctg tgcaagctga agggtggggt tgtagtggac 600 
gagcttggct gcagccgcca gcgagcccct tccagcaaac aggtgaatgg ggtacagaag 660 
caaaggaggc tggcagcaaa cgcaagggaa cggcgcagga tgcacgggct gaaccacgcc 720 
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ttcgaccagc tgcgcaacgt tatcccgtcc ttcaacaacg acaagaagct gtccaaatat 780 
gagaccctac agatggccca gatctacatc aacgctctgt cggagttgct gcagactccc 840 
aatgtcggag agcaaccgcc gccgcccaca gcttcctgca aaaatgacca ccatcacctt 900 
cgcaccgcct cctcctatga aggaggtgcg ggcgcctctg cggtagctgg ggctcagcca 960 
gccccgggag ggggcccgag acctaccccg cccgggcctt gccggactcg cttctcaggc 1020 
ccagcttcct ctgggggtta ctcggtgcag ctggacgctt tgcacttccc agccttcgag 1080 
gacagggccc taacagcgat gatggcacag aaggacctgt cgccttcgct gcccgggggc 1140 
atcctgcagc ctgtacagga ggacaacagc aaaacatctc ccagatccca cagaagtgac 1200 
ggagagtttt ccccccactc tcattacagt gactctgatg aggccagtta ggaaggcaac 1260 
agctccctga aaactgagac aaccaaatgc ccttcctagc gcgcgggaag ccccgtgaca 1320 
aatatccctg caccctttaa tttttggtct gtggtgatcg ttgttagcaa cgacttgact 1380 
tcggacggct gcagctcttc caatcccctt cctcctacct tctccttcct ctgtatgtag 1440 
atactgtatc attatatgta cctttacgtg gcatcgtttc atggtccatg ctgccaatat 1500 
gctgctaaaa tgtcgtatct ctgcctctgg tctgggtttc acttatttta taccttggga 1560 
gttcatcctt gcgtgttgcg ctcactcaca aataagggag ttagtcaatg aagttgtttc 1620 
cccaactgct tgagacccgc attgggtact ttactgaaca cggactattg tgttgttaaa 1680 
atgcaggggc agataagagt atctgtagag cttagacacc aagtgtgtcc agcagtgtgt 1740 
ctagcggacc cagaatacac gcacttcatc actggccgct gcgccgcctt gaagaaactc 1800 
aactgccaat gcagagcaac ttttgatttt aaaaacagcc actcataatc attaaactct 1860 
ttgcaaatgt ttgtttttgc aaatgaaaat taaaaaaaaa catgtagtgt caaaggcatt 1920 
tggtcaattt tattttgctt tgttaacatt agaaaagtta tttattattg cgtatttgga 1980 
cccatttcta cttaattgcc ttttttttac attttctact cgagatcgtt ttattttgat 2040 
ttagcaaatc cagttgccat tgctttatgt atgtatgctc ttttacaaat gataaaataa 2100 
actcggaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2144 
<210> SEQ ID NO 4 
<211> LENGTH, 1572 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1497) .. (1497) 
<223> OTHER INFORMATION, a, c, g, t, unknown or other 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1504) .. (1504) 
<223> OTHER INFORMATION, a, c, g, t, unknown or other 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1526) .. (1526) 
<223> OTHER INFORMATION, a, c, g, t, unknown or other 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1564) .. (1564) 
<223> OTHER INFORMATION, a, c, g, t, unknown or other 
<400> SEQUENCE, 4 
gtcctctgca cacaagaact tttctcgggg tgtaaaaact ctttgattgg ctgctcgcac 60 
gcgcctgccc gcgccctcca ttggctgaga agacacgcga ccggcgcgag gagggggttg 120 
ggagaggagc ggggggagac tgagtggcgc gtgccgcttt ttaaaggggc gcagcgcctt 180 
cagcaaccgg agaagcatag ttgcacgcga cctggtgtgt gatctccgag tgggtggggg 240 
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agggtcgagg agggaaaaaa aaataagacg ttgcagaaga gacccggaaa gggccttttt 
tttggttgag ctggtgtccc agtgctgcct ccgatcctga gcgtccgagc ctttgcagtg 
caatgtcccg cctgctgcat gcagaagagt gggctgaagt gaaggagttg ggagaccacc 
atcgccagcc ccagccgcat catctcccgc aaccgccgcc gccgccgcag ccacctgcaa 
ctttgcaggc gagagagcat cccgtctacc cgcctgagct gtccctcctg gacagcaccg 
acccacgcgc ctggctggct cccactttgc agggcatctg cacggcacgc gccgcccagt 
atttgctaca ttccccggag ctgggtgcct cagaggccgc tgcgccccgg gacgaggtgg 
acggccgggg ggagctggta aggaggagca gcggcggtgc cagcagcagc aagagccccg 
ggccggtgaa agtgcgggaa cagctgtgca agctgaaagg cggggtggtg gtagacgagc 
tgggctgcag ccgccaacgg gccccttcca gcaaacaggt gaatggggtg cagaagcaga 
gacggctagc agccaacgcc agggagcggc gcaggatgca tgggctgaac cacgccttcg 
accagctgcg caatgttatc ccgtcgttca acaacgacaa gaagctgtcc aaatatgaga 
ccctgcagat ggcccaaatc tacatcaacg ccttgtccga gctgctacaa acgcccagcg 
gaggggaaca gccaccgccg cctccagcct cctgcaaaag cgaccaccac caccttcgca 
ccgcggcctc ctatgaaggg ggcgcgggca acgcgaccgc agctggggct cagcaggctt 
ccggagggag ccagcggccg accccgcccg ggagttgccg gactcgcttc tcagccccag 
cttctgcggg agggtactcg gtgcagctgg acgctctgca cttctcgact ttcgaggaca 
gcgccctgac agcgatgatg gcgcaaaaga atttgtctcc ttctctcccc gggagcatct 
tgcagccagt gcaggaggaa aacagcaaaa cttcgcctcg gtcccacaga agcgacgggg 
aattttcccc ccattcccat tacagtgact cggatgaggc aagttaggaa ggtgacagaa 
gcctgaaaac tgagacagaa acaaaactgc cctttcccag tgcgcgggaa gccccgnggt 
taangatccc cgcacccttt aatttnggct ctgcgatggt cgttgtttag caacgacttg 
gctncagatg gt 
<210> SEQ ID NO 5 
<211> LENGTH, 1065 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 5 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1572 
atgtcccgcc tgctgcatgc agaagagtgg gctgaagtga aggagttggg agaccaccat 60 
cgccagcccc agccgcatca tctcccgcaa ccgccgccgc cgccgcagcc acctgcaact 120 
ttgcaggcga gagagcatcc cgtctacccg cctgagctgt ccctcctgga cagcaccgac 180 
ccacgcgcct ggctggctcc cactttgcag ggcatctgca cggcacgcgc cgcccagtat 240 
ttgctacatt ccccggagct gggtgcctca gaggccgctg cgccccggga cgaggtggac 300 
ggccgggggg agctggtaag gaggagcagc ggcggtgcca gcagcagcaa gagccccggg 360 
ccggtgaaag tgcgggaaca gctgtgcaag ctgaaaggcg gggtggtggt agacgagctg 420 
ggctgcagcc gccaacgggc cccttccagc aaacaggtga atggggtgca gaagcagaga 480 
cggctagcag ccaacgccag ggagcggcgc aggatgcatg ggctgaacca cgccttcgac 540 
cagctgcgca atgttatccc gtcgttcaac aacgacaaga agctgtccaa atatgagacc 600 
ctgcagatgg cccaaatcta catcaacgcc ttgtccgagc tgctacaaac gcccagcgga 660 
ggggaacagc caccgccgcc tccagcctcc tgcaaaagcg accaccacca ccttcgcacc 720 
gcggcctcct atgaaggggg cgcgggcaac gcgaccgcag ctggggctca gcaggcttcc 780 
30 
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ggagggagcc agcggccgac cccgcccggg agttgccgga ctcgcttctc agccccagct 
tctgcgggag ggtactcggt gcagctggac gctctgcact tctcgacttt cgaggacagc 
gccctgacag cgatgatggc gcaaaagaat ttgtctcctt ctctccccgg gagcatcttg 
cagccagtgc aggaggaaaa cagcaaaact tcgcctcggt cccacagaag cgacggggaa 
ttttcccccc attcccatta cagtgactcg gatgaggcaa gttag 
<210> SEQ ID NO 6 
<211> LENGTH, 2393 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
agaggcaaga ggctagcggc tggaccactt gtgctggagt ggtaaagaac tatcatgaat 
ccatttactg aaagtgtcca tttctgaact caccctaaag aggacaaaca ccgcaaagta 
gttaaaagtc aggcattcgc gtcggacgtc tgggtttgaa ttctgccctg gcttgactgg 
aaacgcttcc cctatttctt ccgtagcgga ccgggagagc ttactggcgc tctgcgaacc 
ggctggaaag aaacaccgag tcactcgtac agactcttgg tcgcagaact tggctttccg 
ctattggtcc tccagaaccg cttgaaacaa ctggccccag ctggcgcatc agaccgcagt 
gaggaatgcc gcggggcggg tggcgaaggc agggtctgcc cgccagtgga ttcccgggtg 
tcccgcgtgg agcaggcttg cccagctggg aagcccatca aacctcagtc ttggcccaca 
gtgggagaga gaccagtggg tcccagacgg aggccctcgc ccgcttttgg cgacctccac 
tggcgtgaat aaaagcaccc ctctcttacc ctcagaaact gtgggtagca aggtataaaa 
cggagtctgg gaccggtaag tcccaaggtg agcccgtata cagctctgcc atctctgagg 
ggttatgcag attctgagca ggtgtcaggg gctcatgtca gaggagtgcg ggcggactac 
agccctggcg gccgggagga ctcgcaaagg cgccggggaa gagggactgg tgagccccga 
gggagcgggg gacgaggact cgtgctcctc ctcggccccg ctgtccccgt cgtcctcgcc 
ccggtccatg gcctcgggct ccggctgccc tcctggcaag tgtgtgtgca acagttgcgg 
cctggagatc gtggacaaat accttctcaa ggtgaatgac ctatgctggc atgtccggtg 
tctctcctgc agtgtttgca gaacctccct aggaaggcac accagctgtt atattaaaga 
caaagacatt ttctgcaaac ttgattattt cagaaggtat ggaactcgct gctctcgatg 
tgggagacac atccattcta ctgactgggt ccggagagcc aaggggaatg tctatcactt 
ggcatgcttt gcctgctttt cctgcaaaag gcaactttcc acaggagagg agtttgcttt 
ggtggaagag aaagtcctct gcagagtaca ttatgactgc atgctggata atttaaaaag 
agaagtagaa aatgggaatg ggattagtgt ggaaggtgcc ctcctcacag agcaagatgt 
taaccatcca aaaccagcaa aaagagctcg gaccagcttt acagcagatc agcttcaggt 
tatgcaagca caatttgctc aggacaacaa cccagatgca cagacactcc agaaattggc 
agaaaggaca ggcttgagca gacgtgtgat acaggtgtgg tttcagaatt gtagagcacg 
ccacaagaaa cacgtcagtc ctaatcactc atcctccacc ccagtcacag cagtcccacc 
ctccaggctg tctccaccca tgttagaaga aatggcttat tctgcctacg tgccccaaga 
tggaacgatg ttaactgcgc tgcatagtta tatggatgct cattcaccaa caactcttgg 
actccagccc ttgttacccc attcaatgac acaactgcca ataagtcata cctaattctt 
ttttcaggga tagacttgat taaggatata aatttgtcat ttattatgta taaaatacca 
ttgaaaagat attactgtta attttttatt taacacctaa agcatttcca acatcacttt 
32 
840 
900 
960 
1020 
1065 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1740 
1800 
1860 
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gctgcccagg tatgtatcta tagttggcct gcaagacact tttattaatt cttcattttt 
tgtaaaactt atgtttacaa gaagaaaaca aatcaaaaca ttttttgtat tgtctggaaa 
tagttcactc tagtgtgtat ctgttaattt atttgtcatc aaaagagcac tttgcctaaa 
agaaaggact gacaagtgtg caaaatgttt acaatctttt gtgaaattgt agtttatcat 
tagtttgtat ctgtaagtta ttgtaataaa tattacctgt attttttgtt atatacaact 
ttatactttg aagcttgtat ctgtgaattt gcaactgaaa tttattttgc caatgttttc 
tgaatgaact gaataaagct tctgttgtag catgccatgc aaacacatta ttgtgtttgt 
ggttgatgaa ttatggctgt aaataacact atagtttaat aagcccacca ttctgagttt 
attaaacatt ttccattctt gtgaaaattt caaaaaaaaa aaaaaaaaaa aaa 
<210> SEQ ID NO 7 
<211> LENGTH, 1500 
<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 7 
gaattcggca cgagcttcag gaaaagactt ttccccccac tccccctcct ctctgcgagg 
ttccaccctc tggaaaacac aactttccct ctttttctgg agggacaggc cttagtgtgg 
ctgagagagg aagaacagtg ggtcagagag tggttacgtc actgtggcct ttttggaaca 
agacacactg gtggcatcgc tgtcctgcct gttagctttc cttggccttt gggggcggag 
gaggggacac tgcggacacc cacagcctct gaccctgctg gagctggtat gtgacgagca 
gccctcgggc catgtattgg aagagcgatc agatgtttgt gtgtaagctg gagggaaagg 
agatgccgga gctggcggtt ccccgcgaga tgtgccccgg gctcatgtcg gaggagtgcg 
ggcggcctgc agctggcgcc gggaggaccc gcaaaggctc tggggaagaa ggactggtga 
atcccgaggg agccggggac gaggactcct gctcctcctc gggcccgctt tccccgtcgt 
cctcgcccca gtccatggcc tcgggtccga tgtgcccgcc aggcaagtgt gtgtgcagca 
gctgcggcct ggagattgtg gacaaatacc tcctcaaggt gaatgactta tgctggcatg 
tccgctgtct ctcctgcagt gtctgcagaa cgtccctggg aaggcacacg agctgctaca 
ttaaggataa agatattttc tgtaaactcg attacttcag acggtatggg acccgctgtt 
cccgctgtgg caggcacatc cactcgactg actgggtccg cagggcaaag ggcaacgtgt 
atcacctggc ctgctttgcc tgcttttctt gcaagaggca gctgtccacg ggagaggagt 
tcgccttggt ggaggagaag gtcctctgta gagtgcactt tgactgcatg ctggacaatc 
tgaagagaga agtggagaac ggtaatggga ttagtgtgga aggagccctt ctcacagagc 
aagacgtcaa tcatccaaag ccagccaaaa gagctcggac cagcttcaca gccgatcagc 
tccaggttat gcaagcacag ttcgctcagg acaacaaccc agatgcacag accctccaga 
aactggcaga aaggacaggc ttaagcagac gtgtcataca ggtgtggttt cagaactgca 
gggcccgcca taagaaacac gtcagcccaa accattcttc ctcggccccc gtcacagctg 
tcccctcctc caggctgtcc ccacccatct tggaagaaat ggcttattct gcctacgacc 
cccaggatga cgggatgctg actgcgcact catacttgga tgctcaccaa caactcctgg 
actccagccc ttgttacccc atccaatgac ccagctgcca ataagtcata cctaattcct 
tctttcaggg atagaaatga ttgaggttat aaacttgtca ttttattatg tataaaaata 
<210> SEQ ID NO 8 
<211> LENGTH, 751 
34 
1920 
1980 
2040 
2100 
2160 
2220 
2280 
2340 
2393 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
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<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 8 
tgttttgtag ctcaccaaca actcctggac tccagccctt gttaccccat ccaatgaccc 60 
agctgccaat aagtcatacc taattccttc tttcagggat agaaatgatt gaggttataa 120 
acttgtcatt tattatgtat aaaataccat tgagaagata ttaatgttaa ttttttattt 180 
aacactcaaa gcatttcgaa catcctctcg ctgcccaggt atgtatctag agttggcctg 240 
caagacactt ttattgattc ttcattttgg tttttttttg taaaacttat gtttacaaag 300 
aagaaaacaa gtcaaaacat ttttttttgt attgtctgga gatagttggc tcgagtgtgt 360 
gtctattaac ttatttgtca ccaaaagagc actttgcctg aaaggcagga ctgatcgtgt 420 
gcaaaacgtt tacaatcctt tgtgaaactg tagtttatca ttagtttgta cctgtaagtt 480 
attgttataa atattatctg tattttttgt catatacaac tttatacctt gaagcttgta 540 
tctgtgaatt tgcaactgaa atttattttg ccagtgtttt cgggacaagc tgaaggcacg 600 
tccgttgtag catgccgcgc acacccacgg ggtgcctgca cttggagttc tagctgtaaa 660 
taacactcta gtttacaaag cctaccatcc taagttcatt aaacactttg catccttgtg 720 
aaagttgctg cccacttctc ttctgtgtgt a 751 
<210> SEQ ID NO 9 
<211> LENGTH, 1452 
<212> TYPE, DNA 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 9 
ggagcaagtg aagcgtaatt tgaggaagat ggatgagtcc ggagggcgac acccccaacc 60 
cgcccgcccg ccccctccct ccttatgagc gagagagcgc ggcgccggag ccacactgcg 120 
cagagcccgc gccccgccgc cacctcggcc cgcgcgcccg cagcgagcca tgcgtgtccg 180 
cgcggggcgc acggcggggc ccgggcagcg ccatgcagag agcggcaggc ggcggcgccc 240 
ccgggggcag cggcgggagc agcggcggcc ccggcgccgc cttctccatc gactcgctca 300 
tcgggccgcc gccgccgcgc tcgggccacc tgctctacac cggctacccc atgttcatgc 360 
cctaccggcc gctcgtgttg ccgcaggcgc tggcccccgc gccgctgccc gccggcctgc 420 
cgccgctcgc cccgctcgcc tcgttcgccg gccgcctgag caataccttc tgcgcggggc 480 
tgggccaggc ggtgccctcg atggtggcgc tgaccactgc gctgcccagc ttcgcagagc 540 
ccccggacgc ctactacggg cccccggagc tcgccgccgc cgccgcctcc accgcctcgc 600 
gaagcaaccc ggagcccgcg gcccggcgca ctgacggagc gctggacgct gaggagctgc 660 
tgcccgcgcg cgagaaagtg actgaacctc cgccgccccc gcctccgcac ttctctgaga 720 
ctttcccgag tctaccggca gaggggaagg tgtacagctc agatgaagag aagctagagc 780 
ccccagcagg agacccagca ggcagcgagc aggaggaaga gggctcaggc ggtgacagcg 840 
aggacagctt cctggacagt tctgcagggg gcccaggggc tcttctggga cctaaaccga 900 
agctaaaggg aagcccgggg actggcgctg aggaggggac accagtggcc acaggggtca 960 
ccacgcctgg ggggaaaagc cgaaggcggc gcacagcctt caccagcgag cagcttttgg 1020 
agctggagaa ggagtttcac tgcaagaaat acctgagtct gacagagcgc tcccagatcg 1080 
cccacgccct caagctcagt gaggtgcagg tgaagatctg gtttcagaac cgccgggcca 1140 
agtggaagcg catcaaggct ggcaatgtga gcagtcgttc tggggagccg gtgagaaacc 1200 
ccaagattgt agtgcccata cctgtgcacg tcaacaggtt tgctgtgcgc agccagcacc 1260 
36 
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aacagatgga gcaaggagcc cggccctgac cgagctcccc ggaccggaag tcacaggatc 1320 
tgaacctgtg gccgcccaag actcactggg tactgcagcc tagaggggcc tgttgaaccc 1380 
tgctccggga gaggccagcg tattcccggg acacaagact atttggcctg agactgttct 1440 
agagacctca gg 1452 
<210> SEQ ID NO 10 
<211> LENGTH, 1632 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
gacgggtgcg cgggcgggcg gcggcaccat gcagggaagc tgccaggggc cgtgggcagc 60 
gccgctttct gccgcccacc tggcgctgtg agactggcgc tgccaccatg ttccccagcc 120 
ctgctctcac gcccacgccc ttctcagtca aagacatcct aaacctggaa cagcagcagc 180 
gcagcctggc tgccgccgga gagctctctg cccgcctgga ggcgaccctg gcgccctcct 240 
cctgcatgct ggccgccttc aagccagagg cctacgctgg gcccgaggcg gctgcgccgg 300 
gcctcccaga gctgcgcgca gagctgggcc gcgcgccttc accggccaag tgtgcgtctg 360 
cctttcccgc cgcccccgcc ttctatccac gtgcctacag cgaccccgac ccagccaagg 420 
accctagagc cgaaaagaaa gagctgtgcg cgctgcagaa ggcggtggag ctggagaaga 480 
cagaggcgga caacgcggag cggccccggg cgcgacggcg gaggaagccg cgcgtgctct 540 
tctcgcaggc gcaggtctat gagctggagc ggcgcttcaa gcagcagcgg tacctgtcgg 600 
cccccgaacg cgaccagctg gccagcgtgc tgaaactcac gtccacgcag gtcaagatct 660 
ggttccagaa ccggcgctac aagtgcaagc ggcagcggca ggaccagact ctggagctgg 720 
tggggctgcc cccgccgccg ccgccgcctg cccgcaggat cgcggtgcca gtgctggtgc 780 
gcgatggcaa gccatgccta ggggactcgg cgccctacgc gcctgcctac ggcgtgggcc 840 
tcaatcccta cggttataac gcctaccccg cctatccggg ttacggcggc gcggcctgca 900 
gccctggcta cagctgcact gccgcttacc ccgccgggcc ttccccagcg cagccggcca 960 
ctgccgccgc caacaacaac ttcgtgaact tcggcgtcgg ggacttgaat gcggttcaga 1020 
gccccgggat tccgcagagc aactcgggag tgtccacgct gcatggtatc cgagcctggt 1080 
agggaaggga cccgcgtggc gcgaccctga ccgatcccac ctcaacagct ccctgactct 1140 
cggggggaga aggggctccc aacatgaccc tgagtcccct ggattttgca ttcactcctg 1200 
cggagaccta ggaacttttt ctgtcccacg cgcgtttgtt cttgcgcacg ggagagtttg 1260 
tggcggcgat tatgcagcgt gcaatgagtg atcctgcagc ctggtgtctt agctgtcccc 1320 
ccaggagtgc cctccgagag tccatgggca cccccggttg gaactgggac tgagctcggg 1380 
cacgcagggc ctgagatctg gccgcccatt ccgcgagcca gggccgggcg cccgggcctt 1440 
tgctatctcg ccgtcgcccg cccacgcacc cacccgtatt tatgttttta cctattgctg 1500 
taagaaatga cgatcccctt cccattaaag agagtgcgtt gaaaaaaaaa aaaaaaaaaa 1560 
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620 
aaaaaaaaaa aa 1632 
<210> SEQ ID NO 11 
<211> LENGTH, 1406 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 11 
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gagcgcccga gcggagaggc ggcccgggag caggggggcg gcccccactc cggccgggtg 
cccggcccct ggcccctgcc tgccctctag atcgccgccg cagccgccgc tactgggagt 
ctgcctgttg caggacgcac tagccctccc tccatggagt tcggcctgct cagcgaggca 
gaggcccgga gccctgccct gtcgctgtca gacgctggca ctccgcaccc ccagctccca 
gagcacggct gcaagggcca ggagcacagc gactcagaaa aggcctcggc ttcgctgccc 
ggcggctccc cagaggacgg ttcgctgaaa aagaagcagc ggcggcagcg cacgcacttc 
accagccagc agctacagga gctagaggcg accttccaga ggaaccgcta ccccgacatg 
agcacgcgcg aggagattgc cgtgtggacc aacctcaccg aggcccgcgt gcgggtgtgg 
ttcaagaacc ggcgcgccaa atggcggaag cgcgagcgca gccagcaggc cgagctatgc 
aaaggcagct tcgcggcgcc gctcgggggg ctggtgccgc cctacgagga ggtgtacccc 
ggctactcgt acggcaactg gccgcccaag gctcttgccc cgccgctcgc cgccaagacc 
tttccattcg ccttcaactc ggtcaacgtg gggcctctgg cttcgcagcc cgtcttctcg 
ccacccagct ccatcgccgc ctccatggtg ccctccgccg cggctgcccc gggcaccgtg 
ccagggcctg gggccctgca gggcctgggc gggggccccc ccgggctggc tccggccgcc 
gtgtcctccg gggccgtgtc ctgcccttat gcctcggccg ccgccgccgc cgcggctgcc 
gcctcttccc cctacgtcta tcgggacccg tgtaactcga gcctggccag cctgcggctc 
aaagccaaac agcacgcctc cttcagctac cccgctgtgc acgggccgcc cccggcagcc 
aaccttagtc cgtgccagta cgccgtggaa aggcccgtat gagcggcccc gcccgtagat 
catccccgag ggcgggggca acgattcaca gcctccgcgg actggggtca ttttgactgg 
cttgctcccg ccccagggtc tgaaaggggt gtttgggcag ctggggggca ccggctcagg 
agagggcctt cccctcccag ccctgagggg tggactaggc cctacacaca gaccgcgccc 
ctgggactaa agccaggaac agggaccagc tccccggggg ccaactcacc cttggcccat 
cccgccttct ccaggcttcc cctccctcgt tttcaaagat aaatgaaata aacgtgcgcg 
gactgtcaaa aaaaaaaaaa aaaaaa 
<210> SEQ ID NO 12 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1406 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 12 
tgctggcatg tccgctgtct 
<210> SEQ ID NO 13 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 13 
ctggctttgg atgattgacg 
<210> SEQ ID NO 14 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
20 
20 
40 
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<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 14 
tccgatcctg agcgtccgag cctt 
<210> SEQ ID NO 15 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 15 
gcttctgtca ccttcctaac ttgcc 
<210> SEQ ID NO 16 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
6xHis tag 
<400> SEQUENCE, 16 
His His His His His His 
1 5 
<210> SEQ ID NO 17 
<211> LENGTH, 94 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
polynucleotide 
<400> SEQUENCE, 17 
24 
25 
tacaagtccg gactcagatc tcgagctcaa gcttcgaatt ctgcagtcga cggtaccgcg 60 
ggcccgggat ccaccggatc tagataactg atca 94 
<210> SEQ ID NO 18 
<211> LENGTH, 351 
<212> TYPE, PRT 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 18 
Met Ser Arg Leu Leu His Ala Glu Glu 
1 5 
Gly Asp His His Arg His Pro Gln Pro 
20 25 
Trp Ala Glu Val Lys Glu Leu 
10 15 
His His Val Pro Pro Leu Thr 
30 
Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Asp Leu Pro Val Tyr Pro 
35 40 45 
Ala Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp Leu Thr 
50 55 60 
Pro Thr Leu Gln Gly Leu Cys Thr Ala Arg Ala Ala Gln Tyr Leu Leu 
65 70 75 80 
His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg Asp Glu 
85 90 95 
Ala Asp Ser Gln Gly Glu Leu Val Arg Arg Ser Gly Cys Gly Gly Leu 
100 105 110 
Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu Cys Lys Leu 
42 
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115 120 125 
Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg Gln Arg Ala 
130 135 140 
Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg Arg Leu Ala 
145 150 155 160 
Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn His Ala Phe 
165 170 175 
Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp Lys Lys Leu 
180 185 190 
Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu 
195 200 205 
Ser Glu Leu Leu Gln Thr Pro Asn Val Gly Glu Gln Pro Pro Pro Pro 
210 215 220 
Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser 
225 230 235 240 
Tyr Glu Gly Gly Ala Gly Ala Ser Ala Val Ala Gly Ala Gln Pro Ala 
245 250 255 
Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg 
260 265 270 
Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala 
275 280 285 
Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala 
290 295 300 
Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val 
305 310 315 320 
Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly 
325 330 335 
Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser 
340 345 350 
<210> SEQ ID NO 19 
<211> LENGTH, 351 
<212> TYPE, PRT 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 19 
Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu 
1 5 10 15 
Gly Asp His His Arg His Pro Gln Pro His His Val Pro Pro Leu Thr 
20 25 30 
Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Asp Leu Pro Val Tyr Pro 
35 40 45 
Ala Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp Leu Thr 
50 55 60 
Pro Thr Leu Gln Gly Leu Cys Thr Ala Arg Ala Ala Gln Tyr Leu Leu 
65 70 75 80 
His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg Asp Glu 
85 90 95 
Ala Asp Ser Gln Gly Glu Leu Val Arg Arg Ser Gly Cys Gly Gly Leu 
100 105 110 
Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu Cys Lys Leu 
115 120 125 
Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg Gln Arg Ala 
130 135 140 
Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg Arg Leu Ala 
44 
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145 150 155 160 
Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn His Ala Phe 
165 170 175 
Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp Lys Lys Leu 
180 185 190 
Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu 
195 200 205 
Ser Glu Leu Leu Gln Thr Pro Asn Val Gly Glu Gln Pro Pro Pro Pro 
210 215 220 
Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser 
225 230 235 240 
Tyr Glu Gly Gly Ala Gly Ala Ser Ala Val Ala Gly Ala Gln Pro Ala 
245 250 255 
Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg 
260 265 270 
Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala 
275 280 285 
Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala 
290 295 300 
Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val 
305 310 315 320 
Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly 
325 330 335 
Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser 
340 345 350 
<210> SEQ ID NO 20 
<211> LENGTH, 354 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 20 
Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu 
1 5 10 15 
Gly Asp His His Arg Gln Pro Gln Pro His His Leu Pro Gln Pro Pro 
20 25 30 
Pro Pro Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Glu His Pro Val 
35 40 45 
Tyr Pro Pro Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp 
50 55 60 
Leu Ala Pro Thr Leu Gln Gly Ile Cys Thr Ala Arg Ala Ala Gln Tyr 
65 70 75 80 
Leu Leu His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg 
85 90 95 
Asp Glu Val Asp Gly Arg Gly Glu Leu Val Arg Arg Ser Ser Gly Gly 
100 105 110 
Ala Ser Ser Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu 
115 120 125 
Cys Lys Leu Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg 
130 135 140 
Gln Arg Ala Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg 
145 150 155 160 
Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn 
165 170 175 
His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp 
46 
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180 185 190 
Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile 
195 200 205 
Asn Ala Leu Ser Glu Leu Leu Gln Thr Pro Ser Gly Gly Glu Gln Pro 
210 215 220 
Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr 
225 230 235 240 
Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala 
245 250 255 
Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys 
260 265 270 
Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln 
275 280 285 
Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala 
290 295 300 
Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu 
305 310 315 320 
Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg 
325 330 335 
Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu 
340 345 350 
Ala Ser 
<210> SEQ ID NO 21 
<211> LENGTH, 354 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 21 
Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu 
1 5 10 15 
Gly Asp His His Arg Gln Pro Gln Pro His His Leu Pro Gln Pro Pro 
20 25 30 
Pro Pro Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Glu His Pro Val 
35 40 45 
Tyr Pro Pro Glu Leu Ser Leu Leu Asp Ser Thr Asp Pro Arg Ala Trp 
50 55 60 
Leu Ala Pro Thr Leu Gln Gly Ile Cys Thr Ala Arg Ala Ala Gln Tyr 
65 70 75 80 
Leu Leu His Ser Pro Glu Leu Gly Ala Ser Glu Ala Ala Ala Pro Arg 
85 90 95 
Asp Glu Val Asp Gly Arg Gly Glu Leu Val Arg Arg Ser Ser Gly Gly 
100 105 110 
Ala Ser Ser Ser Lys Ser Pro Gly Pro Val Lys Val Arg Glu Gln Leu 
115 120 125 
Cys Lys Leu Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg 
130 135 140 
Gln Arg Ala Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg 
145 150 155 160 
Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn 
165 170 175 
His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp 
180 185 190 
Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile 
195 200 205 
48 
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Asn Ala Leu Ser Glu Leu Leu Gln Thr Pro Ser Gly Gly Glu Gln Pro 
210 215 220 
Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr 
225 230 235 240 
Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala 
245 250 255 
Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys 
260 265 270 
Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln 
275 280 285 
Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala 
290 295 300 
Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu 
305 310 315 320 
Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg 
325 330 335 
Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu 
340 345 350 
Ala Ser 
<210> SEQ ID NO 22 
<211> LENGTH, 356 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 22 
Met Gln Ile Leu Ser Arg Cys Gln Gly Leu Met Ser Glu Glu Cys Gly 
1 5 10 15 
Arg Thr Thr Ala Leu Ala Ala Gly Arg Thr Arg Lys Gly Ala Gly Glu 
20 25 30 
Glu Gly Leu Val Ser Pro Glu Gly Ala Gly Asp Glu Asp Ser Cys Ser 
35 40 45 
Ser Ser Ala Pro Leu Ser Pro Ser Ser Ser Pro Arg Ser Met Ala Ser 
50 55 60 
Gly Ser Gly Cys Pro Pro Gly Lys Cys Val Cys Asn Ser Cys Gly Leu 
65 70 75 80 
Glu Ile Val Asp Lys Tyr Leu Leu Lys Val Asn Asp Leu Cys Trp His 
85 90 95 
Val Arg Cys Leu Ser Cys Ser Val Cys Arg Thr Ser Leu Gly Arg His 
100 105 110 
Thr Ser Cys Tyr Ile Lys Asp Lys Asp Ile Phe Cys Lys Leu Asp Tyr 
115 120 125 
Phe Arg Arg Tyr Gly Thr Arg Cys Ser Arg Cys Gly Arg His Ile His 
130 135 140 
Ser Thr Asp Trp Val Arg Arg Ala Lys Gly Asn Val Tyr His Leu Ala 
145 150 155 160 
Cys Phe Ala Cys Phe Ser Cys Lys Arg Gln Leu Ser Thr Gly Glu Glu 
165 170 175 
Phe Ala Leu Val Glu Glu Lys Val Leu Cys Arg Val His Tyr Asp Cys 
180 185 190 
Met Leu Asp Asn Leu Lys Arg Glu Val Glu Asn Gly Asn Gly Ile Ser 
195 200 205 
Val Glu Gly Ala Leu Leu Thr Glu Gln Asp Val Asn His Pro Lys Pro 
210 215 220 
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Ala Lys Arg Ala Arg Thr Ser Phe Thr Ala Asp Gln Leu Gln Val Met 
225 230 235 240 
Gln Ala Gln Phe Ala Gln Asp Asn Asn Pro Asp Ala Gln Thr Leu Gln 
245 250 255 
Lys Leu Ala Glu Arg Thr Gly Leu Ser Arg Arg Val Ile Gln Val Trp 
260 265 270 
Phe Gln Asn Cys Arg Ala Arg His Lys Lys His Val Ser Pro Asn His 
275 280 285 
Ser Ser Ser Thr Pro Val Thr Ala Val Pro Pro Ser Arg Leu Ser Pro 
290 295 300 
Pro Met Leu Glu Glu Met Ala Tyr Ser Ala Tyr Val Pro Gln Asp Gly 
305 310 315 320 
Thr Met Leu Thr Ala Leu His Ser Tyr Met Asp Ala His Ser Pro Thr 
325 330 335 
Thr Leu Gly Leu Gln Pro Leu Leu Pro His Ser Met Thr Gln Leu Pro 
340 345 350 
Ile Ser His Thr 
355 
<210> SEQ ID NO 23 
<211> LENGTH, 365 
<212> TYPE, PRT 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 23 
Met Tyr Trp Lys Ser Asp Gln Met Phe 
1 5 
Glu Met Pro Glu Leu Ala Val Pro Arg 
20 25 
Val Cys Lys Leu Glu 
10 
Glu Met Cys Pro Gly 
30 
Gly Lys 
15 
Leu Met 
Ser Glu Glu Cys Gly Arg Pro Ala Ala Gly Ala Gly Arg Thr Arg Lys 
35 40 45 
Gly Ser Gly Glu Glu Gly Leu Val Asn Pro Glu Gly Ala Gly Asp Glu 
50 55 60 
Asp Ser Cys Ser Ser Ser Gly Pro Leu Ser Pro Ser Ser Ser Pro Gln 
65 70 75 80 
Ser Met Ala Ser Gly Pro Met Cys Pro Pro Gly Lys Cys Val Cys Ser 
85 90 95 
Ser Cys Gly Leu Glu Ile Val Asp Lys Tyr Leu Leu Lys Val Asn Asp 
100 105 110 
Leu Cys Trp His Val Arg Cys Leu Ser Cys Ser Val Cys Arg Thr Ser 
115 120 125 
Leu Gly Arg His Thr Ser Cys Tyr Ile Lys Asp Lys Asp Ile Phe Cys 
130 135 140 
Lys Leu Asp Tyr Phe Arg Arg Tyr Gly Thr Arg Cys Ser Arg Cys Gly 
145 150 155 160 
Arg His Ile His Ser Thr Asp Trp Val Arg Arg Ala Lys Gly Asn Val 
165 170 175 
Tyr His Leu Ala Cys Phe Ala Cys Phe Ser Cys Lys Arg Gln Leu Ser 
180 185 190 
Thr Gly Glu Glu Phe Ala Leu Val Glu Glu Lys Val Leu Cys Arg Val 
195 200 205 
His Phe Asp Cys Met Leu Asp Asn Leu Lys Arg Glu Val Glu Asn Gly 
210 215 220 
Asn Gly Ile Ser Val Glu Gly Ala Leu Leu Thr Glu Gln Asp Val Asn 
225 230 235 240 
52 
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53 54 
-continued 
His Pro Lys Pro Ala Lys Arg Ala Arg Thr Ser Phe Thr Ala Asp Gln 
245 250 255 
Leu Gln Val Met Gln Ala Gln Phe Ala Gln Asp Asn Asn Pro Asp Ala 
260 265 270 
Gln Thr Leu Gln Lys Leu Ala Glu Arg Thr Gly Leu Ser Arg Arg Val 
275 280 285 
Ile Gln Val Trp Phe Gln Asn Cys Arg Ala Arg His Lys Lys His Val 
290 295 300 
Ser Pro Asn His Ser Ser Ser Ala Pro Val Thr Ala Val Pro 
305 310 315 
Arg Leu Ser Pro Pro Ile Leu Glu Glu Met Ala Tyr Ser Ala 
325 330 
Pro Gln Asp Asp Gly Met Leu Thr Ala His Ser Tyr Leu Asp 
340 345 
Gln Gln Leu Leu Asp Ser Ser Pro Cys Tyr Pro Ile Gln 
355 360 365 
What is claimed is: 
1. A method of biasing differentiation of a neural stem cell 
comprising introducing an expression construct comprising 
an Lhx8 and/or Gbxl gene sequence into the neural stem cell, 
wherein expression of the Lhx8 and/or Gbxl gene sequences 
are effective to bias the neural stem cell to a desired end-stage 
cell type, or to a presumptive end-stage cell having charac-
teristics of the desired end-stage cell type, in vitro, wherein 
the desired end-stage cell type is a cholinergic neuron. 
2. An isolated cell produced by the method of claim 1. 
350 
25 
30 
Ser Ser 
320 
Tyr Asp 
335 
Ala His 
a. providing the population of cells in a vessel· 
b. adding to the vessel one or more copies of a ~ucleic acid 
sequence comprising an Lhx8 and/or Gbxl gene 
sequence under conditions to express said gene 
sequence; 
wherein expression of the gene sequence in one or more cells 
transfected, in vitro, with a copy of the nucleic acid sequence 
is effective to bias the one or more cells to a desired end-stage 
cell type, or to an presumptive end-stage cell having charac-
teristics of the desired end-stage cell type, in vitro, wherein 
the desired end-stage cell type is a cholinergic neuron. 3. A method of biasing differentiation of a neural stem cell 
in vitro comprising: 6. The method of claim 5, the population of cells addition-35 
ally comprising one or more biasable progeny cells. 
a. providing the neural stem cell; 
7. The method of claim 5, the neural stem cells comprising 
human neural stem cells. 
8. An isolated cell produced by the method of claim 5. 
b. preparing a nucleic acid sequence comprising a pro-
moter operatively linked to an expressible sequence that 
comprises an Lhx8 and/or Gbxl gene sequence, the 
nucleic acid sequence comprising a transcription termi-
nation site; and 
9. A method of modifying a neural stem cell to bias differ-
40 
ei:tiation. of said neural stem cell toward a desired end-stage 
c. transfecting said neural stem cell with said nucleic acid 
sequence, in vitro; 
wherein expression of the expressible sequence results in 
biasing the neural stem cell to a desired end-stage cell type, or 45 
to an presumptive end-stage cell having characteristics of the 
desired end-stage cell type, in vitro, wherein the desired end-
stage cell type is cholinergic neuron. 
4. An isolated cell produced by the method of claim 3. 
5. A method of biasing differentiation of one or more cells 50 
in a population of cells comprising neural stem cells, com-
prising: 
d1fferentrnted cell in vitro comprising the step of: 
introducing a nucleic acid sequence into said neural stem 
cell, in vitro, the nucleic acid sequence comprising a 
promoter operatively linked to a developmental control 
gene selected from the group consisting of an Lhx8 and 
Gbxl gene sequence; wherein expression of the devel-
opmental biasing gene increases probability of said 
potent cell to differentiate into a desired end-stage dif-
ferentiated cell, in vitro, wherein the desired end-stage 
cell type is cholinergic neuron. 
* * * * * 
